

10/764,529

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:13:26 ON 07 FEB 2006

10/764,529

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:13:44 ON 07 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

DICTIONARY FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107645291.str



chain nodes :

6 7 8 9 10 12

10/764,529

ring nodes :
1 2 3 4 5
chain bonds :
2-6 4-12 6-7 6-9 7-8 7-10
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-6 6-7 7-8
exact bonds :
2-3 3-4 4-5 4-12 6-9 7-10
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 12:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 12:13:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5444 TO ITERATE

36.7% PROCESSED 2000 ITERATIONS 19 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 104456 TO 113304
PROJECTED ANSWERS: 603 TO 1465

L2 19 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 12:14:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 107916 TO ITERATE

100.0% PROCESSED 107916 ITERATIONS 1081 ANSWERS
SEARCH TIME: 00.00.01

L3 1081 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	166.94	167.15

FILE 'CAPLUS' ENTERED AT 12:14:13 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

10/764,529

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 622 L3

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.06	172.21

FILE 'REGISTRY' ENTERED AT 12:20:41 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5
DICTIONARY FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

10/764,529

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107645292.str



chain nodes :

6 7 8 9 10 12

ring nodes :

1 2 3 4 5 13 14 15 16 17 18

chain bonds :

2-6 5-12 6-7 6-9 7-8 7-10 12-14

ring bonds :

1-2 1-5 2-3 3-4 4-5 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

1-2 1-5 2-6 5-12 6-7 7-8 12-14

exact bonds :

2-3 3-4 4-5 6-9 7-10

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L5 STRUCTURE UPLOADED

=> s 15

SAMPLE SEARCH INITIATED 12:20:56 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5444 TO ITERATE

36.7% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

9 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 104456 TO 113304
PROJECTED ANSWERS: 193 TO 785

L6 9 SEA SSS SAM L5

10/764,529

=> s 15 ful
FULL SEARCH INITIATED 12:21:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 107916 TO ITERATE

100.0% PROCESSED 107916 ITERATIONS 573 ANSWERS
SEARCH TIME: 00.00.02

L7 573 SEA SSS FUL L5

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	166.94	339.15

FILE 'CAPLUS' ENTERED AT 12:21:09 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 17
L8 21 L7

=> d l8 ibib hitstr abs 1-21

L8 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1042064 CAPLUS
DOCUMENT NUMBER: 143:332555
TITLE: Aqueous composition comprising thiazole derivative
INVENTOR(S): Ueno, Ryuji; Hirata, Ryu; Harada, Yasuhiro
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2005089755 A1 20050929 WO 2005-JP5607 20050318

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2004-553956P

P 20040318

OTHER SOURCE(S):

MARPAT 143:332555

IT 183365-33-5 737822-86-5 737822-89-8
 737822-91-2 737822-94-5 737823-04-0
 737823-05-1 737823-09-5 737823-19-7
 737823-29-9 737823-34-6 737823-47-1
 737823-48-2 737823-50-6 737823-52-8
 737823-55-1 737823-67-5 737823-78-8
 737823-84-6 737823-88-0 737823-92-6
 737823-96-0 737824-00-9 737824-05-4
 737824-09-8 737824-13-4 737824-15-6
 737824-17-8 737824-19-0 737824-21-4
 737824-23-6 737824-25-8 737824-27-0
 737824-30-5 737824-32-7 737824-34-9
 737824-40-7 737824-46-3 737824-54-3
 737824-56-5 737824-57-6 737824-60-1
 737824-76-9 737824-82-7 737824-83-8
 737824-84-9 737824-85-0 737824-86-1
 737824-87-2 737824-92-9 737825-15-9
 737825-19-3 737825-30-8 737825-35-3
 737825-38-6 737825-42-2 737825-45-5
 737825-49-9 737825-52-4 737825-56-8
 737825-60-4 737825-64-8 737825-68-2
 737825-70-6 737825-72-8 737825-74-0
 737825-76-2 737825-78-4 737825-80-8
 737825-82-0 737825-84-2 737825-86-4
 737825-88-6 737825-90-0 737825-92-2
 737825-94-4 737825-96-6 737825-98-8
 737826-00-5 737826-02-7 737826-05-0
 737826-07-2 737826-09-4 737826-11-8
 737826-13-0 737826-15-2 737826-16-3
 737826-22-1 737826-27-6 737826-33-4
 737826-39-0 737826-42-5 737826-43-6
 737826-44-7 737826-45-8 737826-48-1
 737826-59-4 737826-71-0 737826-74-3
 737826-77-6 737826-80-1 737826-86-7
 737826-88-9 737826-90-3 737826-92-5
 737826-98-1 737827-00-8 737827-02-0
 737827-05-3 737827-07-5 737827-09-7
 737827-14-4 737827-16-6 737827-21-3
 737827-23-5 737827-26-8 737827-29-1
 737827-34-8 737827-42-8 865294-39-9
 865294-40-2


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation and stability of aqueous composition comprising thiazole derivative)

RN 183365-33-5 CAPLUS


10/764,529

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737822-86-5 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737822-89-8 CAPLUS


CN Acetamide, N-[4-[(1E)-2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737822-91-2 CAPLUS

CN Carbamimidothioic acid, [4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-, methyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

10/764,529


RN 737822-94-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737823-04-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-05-1 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminoiminomethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737823-09-5 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-2-[(aminoiminomethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl


RN 737823-19-7 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-29-9 CAPLUS

CN Acetamide, N-[4-[2-[3-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737823-34-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl


RN 737823-47-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-48-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-chloro-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737823-50-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737823-52-8 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-55-1 CAPLUS


CN Acetamide, N-[4-[2-[4-[(ethylamino)iminomethyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-67-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737823-78-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 737823-84-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-phenyl-, monohydrochloride (9CI)
(CA INDEX NAME)


10/764,529



● HCl

RN 737823-88-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737823-92-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737823-96-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-nitrophenyl)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-00-9 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(methylsulfonyl)phenyl]methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737824-05-4 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(trifluoromethyl)phenyl]methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 737824-09-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-3-pyridinyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737824-13-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-phenoxyphenyl)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-15-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester
(9CI) (CA INDEX NAME)

10/764,529



RN 737824-17-8 CAPLUS


CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)carbonyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-19-0 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737824-21-4 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylcarbonyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 737824-23-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-25-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-27-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-30-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-32-7 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



● HCl


RN 737824-34-9 CAPLUS
CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737824-40-7 CAPLUS
CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(phenylmethyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-46-3 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-54-3 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-56-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-57-6 CAPLUS


CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-60-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(ethylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-76-9 CAPLUS


CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-82-7 CAPLUS


CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-83-8 CAPLUS


CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737824-84-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-85-0 CAPLUS


CN Acetamide, N-[4-[2-[4-[(iminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-86-1 CAPLUS


CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737824-87-2 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]-
(9CI) (CA INDEX NAME)



RN 737824-92-9 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]-
(9CI) (CA INDEX NAME)



RN 737825-15-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[[4-(aminoiminomethyl)amino]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-19-3 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-30-8 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-35-3 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-38-6 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

10/764,529



● 2 HCl


RN 737825-42-2 CAPLUS
CN Acetamide, N-[5-[[4-(2-[[4-(aminoguanidinomethyl)amino]phenyl]ethyl)-2-thiazolyl]-4-(2-dimethylaminomethyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 737825-45-5 CAPLUS
CN Acetamide, N-[4-[2-[[4-[[4-(aminoguanidinomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-2-thiazolyl]-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl


RN 737825-49-9 CAPLUS
 CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 737825-52-4 CAPLUS
 CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-56-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-60-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-64-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]-
, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-68-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-N-
methyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-70-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-[methyl (phenylmethyl)amino]-3-
oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-72-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-oxobutyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

10/764,529




● HCl

RN 737825-74-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737825-76-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



● HCl

RN 737825-78-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-80-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



●2 HCl

RN 737825-82-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(3-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 737825-84-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(phenylacetyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-86-4 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-oxopentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-88-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-oxo-3-[(phenylmethyl)amino]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/764,529

RN 737825-90-0 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-92-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(4-morpholinyl)propyl]-,
dihydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 2-A


● 2 HCl

RN 737825-94-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-

10/764,529


, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-96-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-hexyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 737825-98-8 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-oxo-4-(1-piperidiny)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737826-00-5 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-oxobutyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 737826-02-7 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(methylsulfonyl)phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



RN 737826-05-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737826-07-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/764,529




● HCl

RN 737826-09-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737826-11-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S,2S)-1-[(dimethylamino)carbonyl]-2-hydroxypropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/764,529




● HCl

RN 737826-13-0 CAPLUS

CN Pentanediamide, 2-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]amino]-N,N-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737826-15-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


10/764,529



RN 737826-16-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 737826-22-1 CAPLUS

CN Propanamide, 3-[[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-27-6 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737826-33-4 CAPLUS


CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737826-39-0 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



RN 737826-42-5 CAPLUS


CN Benzamide, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-N-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

10/764,529



RN 737826-43-6 CAPLUS


CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-44-7 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737826-45-8 CAPLUS


CN Acetamide, N-[4-[2-[4-(2-aminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737826-48-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737826-59-4 CAPLUS

10/764,529


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737826-71-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737826-74-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-morpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-77-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737826-80-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl


RN 737826-86-7 CAPLUS
 CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)aminophenyl]ethyl]-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride
 (9CI) (CA INDEX NAME)



● 2 HCl

RN 737826-88-9 CAPLUS
 CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)aminophenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride
 (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl

RN 737826-90-3 CAPLUS
 CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-2-thiazolyl]-, trihydrochloride (9CI) (CA INDEX NAME)




Me

● 3 HCl

RN 737826-92-5 CAPLUS
 CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride
 (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737826-98-1 CAPLUS

CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 737827-00-8 CAPLUS

CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737827-02-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737827-05-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737827-07-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737827-09-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

10/764,529

Absolute stereochemistry.




● 2 HCl

RN 737827-14-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetaminomethyl)-4-[[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 737827-16-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetaminomethyl)-4-[[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

10/764,529

Absolute stereochemistry.




●2 HCl

RN 737827-21-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 737827-23-5 CAPLUS


CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737827-26-8 CAPLUS

CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-2-thiazolyl]-
(9CI) (CA INDEX NAME)



RN 737827-29-1 CAPLUS

CN Acetamide, N-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)aminophenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737827-34-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(2-aminoethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737827-42-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 865294-39-9 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]ethyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 865294-40-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

AB The present invention provides an aqueous composition comprising a thiazole derivative or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alc., boric acid or its salt, and water. The aqueous composition is very stable and can be stored for a long time. For example, a 0.3% aqueous solution of N-[4-[2-[4-

10/764,529

[[amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl]acetamide (I) (pH 6) was prepared using HCl acid and an additive selected from glycerin 2.5%, mannitol 4.7%, or boric acid 1.68%. The solution was stored at 40° in the low-d. polyethylene container. The concentration of the thiazole compound I after 1 mo, 3 mo, and 6 mo was

105.4, 110.6 and 112.3% of the original 100% concentration of I for glycerin, 103.7, 108.4 and 109.6% for mannitol, and 104.9, 106.2, and 108.2% for boric acid, resp.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:991104 CAPLUS

DOCUMENT NUMBER: 142:126546

TITLE: Non-Nucleoside Benzimidazole-Based Allosteric Inhibitors of the Hepatitis C Virus NS5B Polymerase: Inhibition of Subgenomic Hepatitis C Virus RNA Replicons in Huh-7 Cells

AUTHOR(S): Beaulieu, Pierre L.; Bousquet, Yves; Gauthier, Jean; Gillard, James; Marquis, Martin; McKercher, Ginette; Pellerin, Charles; Valois, Serge; Kukolj, George

CORPORATE SOURCE: Departments of Chemistry and Biological Sciences, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S2G5, Can.

SOURCE: Journal of Medicinal Chemistry (2004), 47(27), 6884-6892

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:126546

IT 390813-39-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(non-nucleoside benzimidazole-based allosteric inhibitors of hepatitis C virus NS5B polymerase and inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells)

RN 390813-39-5 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-1-[2-(acetylamino)-4-thiazolyl]-2-(4-hydroxyphenyl)ethyl]-1-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/764,529

IT 852446-55-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(non-nucleoside benzimidazole-based allosteric inhibitors of hepatitis C virus NS5B polymerase and inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells)

RN 852446-55-0 CAPLUS

CN Carbonic acid, 4-[(2S)-2-[2-(acetylamino)-4-thiazolyl]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]phenyl 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



AB A previously disclosed series of nonnucleoside allosteric inhibitors of the NS5B polymerase of the hepatitis C virus (HCV) was optimized to yield novel compds. with improved physicochem. properties and activity in cell-based assays. Replacement of ionizable carboxylic acids with neutral substituents in lead compds. produced inhibitors with cellular permeability and antiviral activity in a cell-based assay of subgenomic HCV RNA replication (replicon EC50 as low as 1.7 μ M). The improvement in potency in this ex vivo model of HCV RNA replication validates, in part, the mechanism by which this class of allosteric benzimidazole derivs. inhibits the polymerase and represents a significant step forward in the discovery of novel HCV therapeutics.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857384 CAPLUS

DOCUMENT NUMBER: 141:350160

TITLE: treatment of vascular hyperpermeable disease using acylaminothiazoles and related compounds as vascular adhesion protein-1 (VAP-1) inhibitors.

INVENTOR(S): Ueno, Ryuji; Nagashima, Akira; Inoue, Takayuki; Ohkubo, Mitsuru; Yoshihara, Kousei

PATENT ASSIGNEE(S): Sucampo Ag, Switz.; Fujisawa Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 269 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087138	A1	20041014	WO 2004-JP4596	20040331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

10/764,529

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

CA 2520957 AA 20041014 CA 2004-2520957 20040331

EP 1608365 A1 20051228 EP 2004-724735 20040331

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: US 2003-458370P P 20030331

WO 2004-JP4596 W 20040331


OTHER SOURCE(S): MARPAT 141:350160

IT 737822-91-2P 737824-46-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(treatment of vascular hyperpermeable disease using acylaminothiazoles
and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)

RN 737822-91-2 CAPLUS


CN Carbamimidothioic acid, [4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-,
methyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 737824-46-3 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



IT 183365-33-5P 737822-86-5P 737822-89-8P
 737822-94-5P 737823-04-0P 737823-05-1P
 737823-09-5P 737823-19-7P 737823-29-9P
 737823-34-6P 737823-37-9P 737823-41-5P
 737823-47-1P 737823-48-2P 737823-50-6P
 737823-52-8P 737823-55-1P 737823-67-5P
 737823-78-8P 737823-84-6P 737823-88-0P
 737823-92-6P 737823-96-0P 737824-00-9P
 737824-05-4P 737824-09-8P 737824-13-4P
 737824-15-6P 737824-17-8P 737824-19-0P
 737824-21-4P 737824-23-6P 737824-25-8P
 737824-27-0P 737824-30-5P 737824-32-7P
 737824-34-9P 737824-40-7P 737824-54-3P
 737824-56-5P 737824-57-6P 737824-60-1P
 737824-76-9P 737824-82-7P 737824-83-8P
 737824-84-9P 737824-85-0P 737824-86-1P
 737824-87-2P 737824-92-9P 737825-09-1P
 737825-15-9P 737825-19-3P 737825-30-8P
 737825-35-3P 737825-38-6P 737825-42-2P
 737825-45-5P 737825-49-9P 737825-52-4P
 737825-56-8P 737825-60-4P 737825-64-8P
 737825-68-2P 737825-70-6P 737825-72-8P
 737825-74-0P 737825-76-2P 737825-78-4P
 737825-80-8P 737825-82-0P 737825-84-2P
 737825-86-4P 737825-88-6P 737825-90-0P
 737825-92-2P 737825-94-4P 737825-96-6P
 737825-98-8P 737826-00-5P 737826-02-7P
 737826-05-0P 737826-07-2P 737826-09-4P
 737826-11-8P 737826-13-0P 737826-15-2P
 737826-16-3P 737826-22-1P 737826-27-6P
 737826-33-4P 737826-36-7P 737826-39-0P
 737826-42-5P 737826-43-6P 737826-44-7P
 737826-45-8P 737826-48-1P 737826-59-4P
 737826-71-0P 737826-74-3P 737826-77-6P
 737826-80-1P 737826-86-7P 737826-88-9P
 737826-90-3P 737826-92-5P 737826-98-1P
 737827-00-8P 737827-02-0P 737827-05-3P
 737827-07-5P 737827-09-7P 737827-14-4P
 737827-16-6P 737827-21-3P 737827-23-5P
 737827-26-8P 737827-29-1P 737827-34-8P
 737827-42-8P


10/764,529

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(treatment of vascular hyperpermeable disease using acylaminothiazoles and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)


RN 183365-33-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737822-86-5 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737822-89-8 CAPLUS


CN Acetamide, N-[4-[(1E)-2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737822-94-5 CAPLUS


CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



10/764,529


RN 737823-04-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-2-thiazolyl]-
(9CI) (CA INDEX NAME)



RN 737823-05-1 CAPLUS


CN Acetamide, N-[4-[2-[4-(aminoiminomethyl)phenyl]ethyl]-2-thiazolyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-09-5 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-2-
[(aminoiminomethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737823-19-7 CAPLUS


CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA
INDEX NAME)

10/764,529



RN 737823-29-9 CAPLUS


CN Acetamide, N-[4-[2-[3-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-34-6 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-37-9 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminooxy)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-41-5 CAPLUS


CN Acetamide, N-[4-[2-[4-[(methyleamino)oxy]methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737823-47-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-48-2 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-chloro-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-50-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/764,529

RN 737823-52-8 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-(acetamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-, ethyl ester, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 737823-55-1 CAPLUS


CN Acetamide, N-[4-[2-[4-[(ethylamino)iminomethyl]amino]phenyl]ethyl]-2-
thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-67-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[4-
(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX
NAME)


10/764,529



● HCl

RN 737823-78-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 737823-84-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-phenyl-, monohydrochloride (9CI)
(CA INDEX NAME)


10/764,529



● HCl

RN 737823-88-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 737823-92-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-(phenylmethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737823-96-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-nitrophenyl)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-00-9 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(methylsulfonyl)phenyl)methyl
]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737824-05-4 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 737824-09-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-3-pyridinyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737824-13-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-phenoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-15-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-17-8 CAPLUS


CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)carbonyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-19-0 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737824-21-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylcarbonyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-23-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-25-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-27-0 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



● HCl


RN 737824-30-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737824-32-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-34-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-40-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(phenylmethyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-54-3 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-56-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-57-6 CAPLUS


CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-60-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(ethylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-76-9 CAPLUS


CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-82-7 CAPLUS


CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-83-8 CAPLUS


CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-84-9 CAPLUS


CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737824-85-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(iminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)




RN 737824-86-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737824-87-2 CAPLUS


CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



10/764,529


RN 737824-92-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-09-1 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminooxy)methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-15-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-19-3 CAPLUS

CN Benzoic acid, 4-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-30-8 CAPLUS

CN Benzamide, 4-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-35-3 CAPLUS

CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-38-6 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

10/764,529



● 2 HCl


RN 737825-42-2 CAPLUS
CN Acetamide, N-[5-[[4-(4-acetyl-1-piperazinyl)methyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-5-(methanesulfonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 737825-45-5 CAPLUS
CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methanesulfonyl)-1-piperazinyl]methyl]-2-thiazolyl]-5-[[4-(methanesulfonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl


RN 737825-49-9 CAPLUS
 CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 737825-52-4 CAPLUS
 CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-56-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-60-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetamino)-N-[2-(acetamino)ethyl]-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA
INDEX NAME)


10/764,529



● HCl

RN 737825-64-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-68-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-70-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-[methyl(phenylmethyl)amino]-3-
oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-72-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-oxobutyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

10/764,529




● HCl

RN 737825-74-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737825-76-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



● HCl

RN 737825-78-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-80-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737825-82-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(3-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737825-84-2 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(phenylacetyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529




● HCl

RN 737825-86-4 CAPLUS
 CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-oxopentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-88-6 CAPLUS
 CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-oxo-3-[(phenylmethyl)amino]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/764,529

RN 737825-90-0 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-92-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(4-morpholinyl)propyl]-,
dihydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 2-A


● 2 HCl

RN 737825-94-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-

10/764,529


, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-96-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-hexyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 737825-98-8 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-oxo-4-(1-piperidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737826-00-5 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 737826-02-7 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(4-methylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



RN 737826-05-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737826-07-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



● HCl

RN 737826-09-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737826-11-8 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S,2S)-1-[(dimethylamino)carbonyl]-2-hydroxypropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/764,529




● HCl

RN 737826-13-0 CAPLUS

CN Pentanediamide, 2-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]amino]-N,N-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737826-15-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


10/764,529



RN 737826-16-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 737826-22-1 CAPLUS

CN Propanamide, 3-[[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-27-6 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737826-33-4 CAPLUS


CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737826-36-7 CAPLUS


CN Carbamic acid, [4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 737826-39-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-42-5 CAPLUS


CN Benzamide, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-N-(aminoiminomethyl)- (9CI) (CA INDEX NAME)



RN 737826-43-6 CAPLUS


CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-44-7 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737826-45-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-aminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737826-48-1 CAPLUS


CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737826-59-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737826-71-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-

10/764,529


dioxido-4-thiomorpholinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI)
(CA INDEX NAME)



● 2 HCl

RN 737826-74-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-morpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737826-77-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-80-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 737826-86-7 CAPLUS
CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



RN 737826-88-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 737826-90-3 CAPLUS

10/764,529

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-2-thiazolyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


Me

● 3 HCl

RN 737826-92-5 CAPLUS


CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



● HCl


RN 737826-98-1 CAPLUS
CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 737827-00-8 CAPLUS
CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA
INDEX NAME)


10/764,529



● HCl

RN 737827-02-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 737827-05-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737827-07-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737827-09-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

10/764,529

Absolute stereochemistry.




● 2 HCl

RN 737827-14-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 737827-16-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

10/764,529

Absolute stereochemistry.




●2 HCl

RN 737827-21-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 737827-23-5 CAPLUS


CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737827-26-8 CAPLUS

CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737827-29-1 CAPLUS

CN Acetamide, N-[2-(2-(2-(2-amino-1H-benzimidazol-5-yl)ethyl)-4-(acetamino)phenyl)ethyl]-5-thiazolylmethyl-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737827-34-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(2-aminoethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737827-42-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 737827-47-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of vascular hyperpermeable disease using acylaminothiazoles and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)

RN 737827-47-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[2-[4-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



IT 183365-28-8P 183365-29-9P 737822-88-7P

737822-90-1P 737822-92-3P 737822-93-4P
737823-07-3P 737823-10-8P 737823-11-9P
737823-20-0P 737823-21-1P 737823-22-2P
737823-30-2P 737823-31-3P 737823-32-4P
737823-33-5P 737823-35-7P 737823-36-8P
737823-39-1P 737823-40-4P 737823-49-3P
737823-51-7P 737823-53-9P 737823-54-0P
737823-74-4P 737823-75-5P 737823-76-6P
737823-77-7P 737823-79-9P 737823-80-2P
737823-81-3P 737823-82-4P 737823-83-5P
737823-85-7P 737823-86-8P 737823-87-9P
737823-89-1P 737823-90-4P 737823-91-5P
737823-93-7P 737823-94-8P 737823-95-9P
737823-97-1P 737823-98-2P 737823-99-3P
737824-01-0P 737824-02-1P 737824-03-2P
737824-04-3P 737824-06-5P 737824-07-6P
737824-08-7P 737824-10-1P 737824-14-5P
737824-18-9P 737824-20-3P 737824-22-5P
737824-24-7P 737824-29-2P 737824-31-6P
737824-33-8P 737824-37-2P 737824-38-3P
737824-39-4P 737824-43-0P 737824-44-1P
737824-45-2P 737824-52-1P 737824-53-2P
737824-55-4P 737824-58-7P 737824-59-8P
737824-67-8P 737824-68-9P 737824-69-0P
737824-71-4P 737824-77-0P 737824-78-1P
737824-79-2P 737824-80-5P 737824-81-6P
737824-88-3P 737824-89-4P 737824-90-7P
737824-91-8P 737824-94-1P 737824-95-2P
737825-10-4P 737825-11-5P 737825-12-6P
737825-13-7P 737825-14-8P 737825-16-0P
737825-18-2P 737825-25-1P 737825-27-3P
737825-28-4P 737825-31-9P 737825-32-0P
737825-33-1P 737825-34-2P 737825-36-4P
737825-37-5P 737825-40-0P 737825-41-1P
737825-44-4P 737825-48-8P 737825-50-2P
737825-51-3P 737825-53-5P 737825-54-6P
737825-55-7P 737825-57-9P 737825-58-0P
737825-59-1P 737825-61-5P 737825-62-6P
737825-63-7P 737825-65-9P 737825-66-0P
737825-67-1P 737825-69-3P 737825-71-7P
737825-73-9P 737825-75-1P 737825-77-3P
737825-79-5P 737825-85-3P 737825-87-5P
737825-89-7P 737825-91-1P 737825-93-3P
737825-95-5P 737825-97-7P 737825-99-9P
737826-01-6P 737826-03-8P 737826-04-9P
737826-08-3P 737826-10-7P 737826-12-9P
737826-14-1P 737826-17-4P 737826-18-5P
737826-19-6P 737826-20-9P 737826-21-0P
737826-23-2P 737826-24-3P 737826-25-4P
737826-26-5P 737826-28-7P 737826-29-8P
737826-30-1P 737826-31-2P 737826-32-3P
737826-34-5P 737826-35-6P 737826-37-8P
737826-38-9P 737826-40-3P 737826-47-0P
737826-49-2P 737826-68-5P 737826-69-6P
737826-70-9P 737826-73-2P 737826-76-5P
737826-79-8P 737826-81-2P 737826-82-3P
737826-84-5P 737826-85-6P 737826-87-8P
737826-89-0P 737826-91-4P 737826-93-6P
737826-94-7P 737826-97-0P 737826-99-2P

10/764,529

737827-01-9P 737827-04-2P 737827-06-4P
737827-08-6P 737827-10-0P 737827-13-3P
737827-15-5P 737827-17-7P 737827-20-2P
737827-22-4P 737827-25-7P 737827-28-0P
737827-31-5P 737827-32-6P 737827-33-7P
737827-35-9P 737827-43-9P 737827-44-0P
737827-45-1P 737827-46-2P 740816-44-8P
776326-32-0P 776326-33-1P 776326-34-2P
776326-42-2P 776326-43-3P 776326-45-5P
776326-51-3P 776326-53-5P 776327-07-2P
776327-23-2P 776327-31-2P 776327-34-5P
776327-40-3P 776327-70-9P 776327-71-0P
776327-87-8P 776327-92-5P 776327-94-7P
776327-96-9P 776327-98-1P 776328-14-4P
776328-17-7P 776328-27-9P 776328-41-7P
776328-45-1P 776328-48-4P 776328-56-4P
777071-34-8P 777071-37-1P 777071-46-2P
777071-49-5P 777081-32-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(treatment of vascular hyperpermeable disease using acylaminothiazoles and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)

RN 183365-28-8 CAPLUS


CN Acetamide, N-[4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 183365-29-9 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737822-88-7 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

o


10/764,529



RN 737822-90-1 CAPLUS


CN Acetamide, N-[4-[(1E)-2-(4-aminophenyl)ethenyl]-2-thiazolyl] - (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 737822-92-3 CAPLUS

CN Benzamide, N-[[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]thioxomethyl] - (9CI) (CA INDEX NAME)



RN 737822-93-4 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]-2-thiazolyl] - (9CI) (CA INDEX NAME)



RN 737823-07-3 CAPLUS


CN Acetamide, N-[4-[2-(4-cyanophenyl)ethyl]-2-thiazolyl] - (9CI) (CA INDEX NAME)

10/764,529




RN 737823-10-8 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetamino)-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737823-11-9 CAPLUS


CN Acetamide, N-[4-[2-[2-(acetamino)-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-20-0 CAPLUS


CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-21-1 CAPLUS


CN Acetamide, N-[4-[2-[4-(bromomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737823-22-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[(diethylamino)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737823-30-2 CAPLUS

CN Acetamide, N-[4-[2-(3-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737823-31-3 CAPLUS

CN Acetamide, N-[4-[2-(3-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-32-4 CAPLUS


CN Carbamic acid, [[3-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-33-5 CAPLUS


10/764,529

CN Carbamic acid, [[3-[2-[2-(acetylamino)-5-bromo-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737823-35-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737823-36-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-bromo-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-39-1 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



10/764,529


RN 737823-40-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[[[1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737823-49-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-chloro-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-51-7 CAPLUS

CN Carbamic acid, [[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]methyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737823-53-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[(1E)-2-(4-nitrophenyl)ethenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/764,529



RN 737823-54-0 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 737823-74-4 CAPLUS

CN Acetamide, N-[5-[4-(methylthio)phenyl]-4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 737823-75-5 CAPLUS

CN Acetamide, N-[5-[4-(methylsulfonyl)phenyl]-4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/764,529




RN 737823-76-6 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-77-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



10/764,529


RN 737823-79-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 737823-80-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 737823-81-3 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 737823-82-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)


10/764,529



RN 737823-83-5 CAPLUS
CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737823-85-7 CAPLUS
CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(phenylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 737823-86-8 CAPLUS
CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-phenyl- (9CI) (CA INDEX NAME)

10/764,529




RN 737823-87-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(phenylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-89-1 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737823-90-4 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

10/764,529




RN 737823-91-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-93-7 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(phenylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737823-94-8 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

10/764,529




RN 737823-95-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(phenylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-97-1 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-98-2 CAPLUS


10/764,529

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 737823-99-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-01-0 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[(4-methylthio)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-02-1 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737824-03-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)


10/764,529



RN 737824-04-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A






RN 737824-06-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737824-07-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 737824-08-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-


10/764,529

(trifluoromethyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)



RN 737824-10-1 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-
(9CI) (CA INDEX NAME)



RN 737824-14-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-18-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(4-acetyl-1-piperazinyl)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-20-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-22-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-thiomorpholinylcarbonyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-24-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-29-2 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-31-6 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-33-8 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-37-2 CAPLUS


CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737824-38-3 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737824-39-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-phenyl-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-43-0 CAPLUS

CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-(phenylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737824-44-1 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-(phenylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

CC(=O)Nc1cnc(Cc2ccccc2)c(s1)CCc3ccc(N)cc3

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(phenylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




CN Acetamide, N-[5-[[4-(methylthio)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




CN Acetamide, N-[5-[[4-(methylsulfonyl)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-55-4 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-58-7 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-59-8 CAPLUS

CN Carbamimidothioic acid, [4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, methyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 737824-67-8 CAPLUS


CN Acetamide, N-[5-[[4-(ethylthio)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-68-9 CAPLUS


CN Acetamide, N-[5-[[4-(ethylsulfonyl)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-69-0 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(ethylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-71-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 737824-77-0 CAPLUS

CN Benzoic acid, 4-[(1Z)-2-[2-(acetamino)-5-[[4-(methylthio)phenyl]methyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



RN 737824-78-1 CAPLUS


CN Benzoic acid, 4-[(1Z)-2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 737824-79-2 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



10/764,529


RN 737824-80-5 CAPLUS

CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)




RN 737824-81-6 CAPLUS

CN Acetamide, N-[4-[2-[4-(chloromethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737824-88-3 CAPLUS

CN Acetamide, N-[4-[2-[4-(chloromethyl)phenyl]ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)




RN 737824-89-4 CAPLUS

CN Acetamide, N-[4-[2-[4-(cyanomethyl)phenyl]ethyl]-2-thiazolyl]-(9CI) (CA


10/764,529

INDEX NAME)



RN 737824-90-7 CAPLUS


CN Benzeneethanimidic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737824-91-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-94-1 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[4-(methylsulfinyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-95-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfinyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737825-10-4 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[2-(acetylamino)-5-[4-(methylthio)phenyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



RN 737825-11-5 CAPLUS


CN Benzoic acid, 4-[(1E)-2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737825-12-6 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



10/764,529


RN 737825-13-7 CAPLUS

CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737825-14-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[[[1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)




RN 737825-16-0 CAPLUS

CN Acetamide, N-[4-[2-[4-(bromomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)


CC(=O)Nc1nc(Cc2ccc(cc2)S(=O)(=O)C)sc1CCc3ccc(cc3)CBr

Carbamic acid, [[4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]methyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




CN Acetamide, N-[5-[(4-iodophenyl)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737825-27-3 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 737825-28-4 CAPLUS


CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



10/764,529


RN 737825-31-9 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 737825-32-0 CAPLUS


CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 737825-33-1 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737825-34-2 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-36-4 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529




RN 737825-37-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-40-0 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



10/764,529


RN 737825-41-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(dimethylamino)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-44-4 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(4-acetyl-1-piperazinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-48-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/764,529



RN 737825-50-2 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 737825-51-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-thiomorpholinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737825-53-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737825-54-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-55-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-,


10/764,529

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737825-57-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737825-58-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-59-1 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737825-61-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737825-62-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-(4-aminophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-63-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737825-65-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-[(methanesulfonyl)amino]ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 737825-66-0 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-[(methanesulfonyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 737825-67-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-[(methanesulfonyl)amino]ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737825-69-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-71-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-[methyl(phenylmethyl)amino]-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-73-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(dimethylamino)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/764,529



RN 737825-75-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(2R)-2-[(dimethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737825-77-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(2S)-2-[(dimethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/764,529


RN 737825-79-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(methylsulfonyl)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737825-85-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-[(phenylacetyl)amino]ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-87-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[5-(dimethylamino)-5-oxopentyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



10/764,529


RN 737825-89-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-oxo-3-
[(phenylmethyl)amino]propyl]amino]carbonyl]-4-
thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)



RN 737825-91-1 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[6-(dimethylamino)-6-
oxohexyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-93-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(4-
morpholinyl)propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]
bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737825-95-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-97-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(hexylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737825-99-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-oxo-4-(1-piperidinyl)butyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-01-6 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(4-morpholinyl)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-03-8 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylthio)phenyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-04-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/764,529



RN 737826-08-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737826-10-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



RN 737826-12-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S,2S)-1-[(dimethylamino)carbonyl]-2-hydroxypropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737826-14-1 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-4-amino-1-[(dimethylamino)carbonyl]-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737826-17-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(methoxymethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-18-5 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-formyl-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-19-6 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(2S)-2-[(dimethylamino)carbonyl]-1-pyrrolidinyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CCN(C)C(=O)[C@H]1SCCN1Cc2sc(CCN(C)C)nc2CCc3ccc(NC(=O)OCC)cc3

2-Pyrrolidinecarboxamide, 1-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

CC(=O)Nc1c[nH]c2c1sc2C3CCN(C3)C(=O)N


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(2S)-2-
[(dimethylamino)carbonyl]-1-pyrrolidinyl]methyl]-4-
thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

CCOC(=O)NC(=Nc1ccc(cc1)CCc2cnc(s2)C3CCN(C3)C(=O)N(C)C)NC(=O)OC(C)(C)C

10/764,529


RN 737826-23-2 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 737826-24-3 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-25-4 CAPLUS


CN Propanamide, 3-[[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 737826-26-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-28-7 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 737826-29-8 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-30-1 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetylamino)-4-[2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethyl]- (9CI) (CA INDEX NAME)



RN 737826-31-2 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-32-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-34-5 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-35-6 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-37-8 CAPLUS


CN Carbamic acid, [4-[[2-(acetylamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-38-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methoxycarbonyl)amino]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737826-40-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.

CCOC(=O)C1CCN(CC1Cc2sc(NC(C)=O)n2C/C=C/c3ccc([N+](=O)[O-])cc3)CC1

CN Carbamic acid, [2-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




CN Carbamic acid, [[2-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]ethyl]carbamimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



CN Acetamide, N-[5-[[3-(methylsulfonyl)phenyl]methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Page 186

10/764,529




RN 737826-69-6 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737826-70-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



10/764,529


RN 737826-73-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-76-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-morpholinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-79-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(3-oxo-1-piperazinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/764,529



RN 737826-81-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 737826-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 737826-84-5 CAPLUS
 CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(1-piperazinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
 (9CI) (CA INDEX NAME)

10/764,529



RN 737826-85-6 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-87-8 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-89-0 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737826-91-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 737826-93-6 CAPLUS
 CN 2-Propenoic acid, 3-[2-(acetamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]-, ethyl ester
 (9CI) (CA INDEX NAME)



RN 737826-94-7 CAPLUS


10/764,529

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 737826-97-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[3-(dimethylamino)-3-oxopropyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-99-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[3-(methylamino)-3-oxopropyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737827-01-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(3-amino-3-oxopropyl)-4-


10/764,529

thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)



RN 737827-04-2 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737827-06-4 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737827-08-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(aminocarbonyl)-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737827-10-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


10/764,529



RN 737827-13-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(3R)-3-[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737827-15-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(3R)-3-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. .


10/764,529



RN 737827-17-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 737827-20-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(3S)-3-[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



RN 737827-22-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(3S)-3-[(methyldimethylamino)carbonyl]-1-piperidin-1-ylmethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737827-25-7 CAPLUS


CN Acetamide, N-[4-[2-(3,4-diaminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737827-28-0 CAPLUS


CN Acetamide, N-[4-[2-(3,4-diaminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737827-31-5 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 737827-32-6 CAPLUS


CN Acetamide, N-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

10/764,529




RN 737827-33-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(acetylmethylamino)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737827-35-9 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 737827-43-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(1E)-2-[4-(methylsulfonyl)phenyl]ethenyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/764,529



RN 737827-44-0 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737827-45-1 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737827-46-2 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 740816-44-8 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino][[(1,1-dimethylethoxy)carbonyl]imino]methyl]amino]phenyl]ethyl]-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)

10/764,529




RN 776326-32-0 CAPLUS

CN Acetamide, N-[4-[2-(4-cyanophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 776326-33-1 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 776326-34-2 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)




10/764,529

RN 776326-42-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[[Z]-bis[[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 776326-43-3 CAPLUS

CN Carbamic acid, [[C(Z)]-[4-[2-[2-(acetylamino)-5-[(3-pyridinylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 776326-45-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-[[[Z]-bis[[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



RN 776326-51-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[Z]-bis[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 776326-53-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[Z]-bis[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

CC(=O)O[C@H]1CCN(CC1)C(=O)c2sc(C#N)c2CCc3ccc(NC(=N)C(=O)OCC)cc3


CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[[(Z)-bis[[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

CCOC(=O)C(=O)Nc1nc(NC2=CC=CC=C2CCc3csc(C4=CC=C(C(=O)OC)C=C4)c3)c(=O)OCC5=CC=C(C(=O)NC)C=C5

CN Acetamide, N-[5-[(dimethylamino)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Page 207


10/764,529



RN 776327-31-2 CAPLUS


CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 776327-34-5 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 776327-40-3 CAPLUS

CN Acetamide, N-[5-[(4-(methylsulfonyl)-1-piperazinyl)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



RN 776327-70-9 CAPLUS

CN Carbamic acid, [[C(Z)]-[4-[2-[2-(acetylamino)-5-[[4-(pyridinylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 776327-71-0 CAPLUS

CN Carbamic acid, [[C(Z)]-[4-[2-[2-(acetylamino)-5-[[3-(pyridinylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/764,529

RN 776327-87-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 776327-92-5 CAPLUS

Acetamide, N-[5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 776327-94-7 CAPLUS

CN Acetamide, N-[5-(4-morpholinylmethyl)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



RN 776327-96-9 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



Double bond geometry as shown.



RN 776327-98-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-[(Z)-[bis[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 776328-14-4 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[Z)-bis[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



RN 776328-17-7 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetamino)-4-[2-[4-[[Z)-bis[[[(1,1-dimethylethoxy) carbonyl] amino]methylene]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 776328-27-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetamino)-4-[2-[4-[[Z)-bis[[[(1,1-dimethylethoxy) carbonyl] amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 776328-41-7 CAPLUS


CN Acetamide, N-[4-[2-(3,4-dinitrophenyl)ethenyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 776328-45-1 CAPLUS


CN Acetamide, N-[4-[2-(3,4-dinitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 776328-48-4 CAPLUS

CN Acetamide, N-[5-[(methilamino)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 776328-56-4 CAPLUS

CN Benzeneacetamide, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]- (9CI) (CA INDEX NAME)

CC(=O)Nc1cc(CCNCCc2ccc(cc2)CC(=O)N)sc1

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[(Z)-bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

CCOC(=O)[C@H]1CCCN(C1)Cc2sc(NC(C)=O)n2CCc3ccc(NC(=O)N(C(=O)OCC)C(=O)OCC)cc3

CN 3-Piperidinecarboxylic acid, 1-[[[2-(acetylamino)-4-[2-[4-[[[Z)-bis[[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)


Chemical structure of a thiazole derivative. The thiazole ring is substituted with an acetyl group (AcNH-), a 4-(4-(4-(4-(tert-butoxycarbonylhydrazono)phenyl)butyl)phenyl)phenyl group, and a 2-(2-(R)-2-carboxyethyl)ethyl group. The R group is defined as a 2-(2-(2-(2-(tert-butoxycarbonylhydrazono)phenyl)ethyl)ethyl)ethyl group.

10/764,529

RN 777071-46-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[[Z]-bis[[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 777071-49-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[[Z]-bis[[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 777081-32-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB A method for treating a vascular hyperpermeable disease (except macular edema), comprises administration of a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. Thus, N-[4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-2-yl]acetamide (preparation given) was refluxed with HCl and cyanamide in EtOH for 26 h to give title compound (I). I inhibited human plasma VAP-1 (SSAO) with IC₅₀ = 0.15 μ M.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:648516 CAPLUS

DOCUMENT NUMBER: 141:190785

TITLE: Preparation of thiazole derivatives as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases

INVENTOR(S): Inoue, Takayuki; Tojo, Takashi; Morita, Masataka; Ohkubo, Mitsuru; Yoshihara, Kousei; Nagashima, Akira

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2004067521 A1 20040812 WO 2004-JP708 20040127
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
 CA 2514573 AA 20040812 CA 2004-2514573 20040127
 US 2004259923 A1 20041223 US 2004-764529 20040127
 EP 1587800 A1 20051026 EP 2004-705519 20040127
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPLN. INFO.: US 2003-442509P P 20030127
 US 2003-458369P P 20030331
 US 2003-517377P P 20031106
 WO 2004-JP708 W 20040127


OTHER SOURCE(S): MARPAT 141:190785

IT **737822-91-2P**, Methyl N-[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]imidothiocarbamate hydroiodide **737823-19-7P**,
 N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]thiazol-2-yl]acetamide
737823-37-9P, N-[4-[2-[4-[(Aminooxy)methyl]phenyl]ethyl]thiazol-2-yl]acetamide **737824-46-3P**, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737826-45-8P**,
 N-[4-[2-[4-(2-Aminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (VAP-1 inhibitor; preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)
 RN 737822-91-2 CAPLUS
 CN Carbamimidothioic acid, [4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-, methyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 737823-19-7 CAPLUS
 CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-37-9 CAPLUS
 CN Acetamide, N-[4-[2-[4-[(aminooxy)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI)


10/764,529

(CA INDEX NAME)




RN 737824-46-3 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737826-45-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-aminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **183365-33-5P**, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]thiazol-2-yl]acetamide **737822-86-5P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide **737822-89-8P**, N-[4-[(E)-2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethenyl]thiazol-2-yl]acetamide **737822-94-5P**, N-[4-[2-[4-[(4,5-Dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]thiazol-2-yl]acetamide **737823-04-0P**, N-[4-[2-[4-(Ethanimidoylamino)phenyl]ethyl]thiazol-2-yl]acetamide **737823-05-1P**, N-[4-[2-[4-[Amino(imino)methyl]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride **737823-09-5P**, N-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]-2-[[amino(imino)methyl]amino]aceta

mide hydrochloride **737823-29-9P**, N-[4-[2-[3-
 [[Amino(imino)methyl]amino]phenyl]ethyl]-5-bromothiazol-2-yl]acetamide
 hydrochloride **737823-34-6P**, N-[4-[2-[4-
 [[Amino(imino)methyl]amino]phenyl]ethyl]-5-bromothiazol-2-yl]acetamide
 hydrochloride **737823-41-5P**, N-[4-[2-[4-
 [[(Methyleneamino)oxy]methyl]phenyl]ethyl]thiazol-2-yl]acetamide
737823-47-1P, N-[4-[2-[4-[[[Amino(imino)methyl]amino]phenyl]
]ethyl]thiazol-2-yl]acetamide **737823-48-2P**, N-[4-[2-[4-
 [[Amino(imino)methyl]amino]phenyl]ethyl]-5-chlorothiazol-2-yl]acetamide
 hydrochloride **737823-50-6P**, N-[4-[2-[4-
 [[Amino(imino)methyl]amino]methyl]phenyl]ethyl]thiazol-2-yl]acetamide
 hydrochloride **737823-52-8P**, Ethyl 2-(acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]thiazole-5-carboxylate
 hydrochloride **737823-55-1P**, N-[4-[2-[4-
 [[(Ethylamino)(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide
737823-67-5P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
 5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride
737823-78-8P, 2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]-N-methylthiazole-5-carboxamide
 hydrochloride **737823-84-6P**, 2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]-N-phenylthiazole-5-carboxamide
 hydrochloride **737823-88-0P**, 2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]-N,N-dimethylthiazole-5-
 carboxamide hydrochloride **737823-92-6P**, 2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]-N-benzylthiazole-5-carboxamide
 hydrochloride **737823-96-0P**, 2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-nitrobenzyl)thiazole-5-
 carboxamide hydrochloride **737824-00-9P**, 2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-
 (methylsulfonyl)benzyl]thiazole-5-carboxamide hydrochloride
737824-05-4P, 2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-
 (trifluoromethyl)benzyl]thiazole-5-carboxamide hydrochloride
737824-09-8P, 2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]-N-(3-pyridinyl)thiazole-5-
 carboxamide dihydrochloride **737824-13-4P**, 2-(Acetylamino)-4-[2-
 [4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-phenoxybenzyl)thiazole-5-
 carboxamide hydrochloride **737824-15-6P**, Ethyl
 4-[[2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
 l-5-yl]carbonyl]-1-piperazinecarboxylate **737824-17-8P**,
 N-[5-[(4-Acetyl-1-piperazinyl)carbonyl]-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide
737824-19-0P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
 5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]thiazol-2-yl]acetamide
 hydrochloride **737824-21-4P**, N-[4-[2-[4-
 [[Amino(imino)methyl]amino]phenyl]ethyl]-5-(4-
 thiomorpholinylcarbonyl)thiazol-2-yl]acetamide hydrochloride
737824-23-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-
 5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]thiazol-2-yl]acetamide
 hydrochloride **737824-25-8P**, Ethyl 1-[[2-(acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-4-
 piperidinecarboxylate hydrochloride **737824-27-0P**,
 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
 l-5-yl]carbonyl]-4-piperidinecarboxamide hydrochloride
737824-30-5P, 1-[[2-(Acetylamino)-4-[2-[4-
 [[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N-methyl-4-
 piperidinecarboxamide hydrochloride **737824-32-7P**,
 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazo
 l-5-yl]carbonyl]-N,N-dimethyl-4-piperidinecarboxamide hydrochloride

737824-34-9P, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-phenylthiazol-2-yl]acetamide hydrochloride **737824-40-7P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-benzylthiazol-2-yl]acetamide hydrochloride **737824-54-3P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-56-5P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride **737824-57-6P**, N-[4-[2-[4-[Hydrazino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-60-1P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(ethylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride **737824-76-9P**, N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-82-7P**, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-83-8P**, N-[4-[2-[4-[(4,5-Dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-84-9P**, N-[4-[2-[4-(Ethanimidoylamino)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-85-0P**, N-[4-[2-[4-[(Iminomethyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide **737824-86-1P**, N-[4-[2-[4-[Hydrazino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide **737824-87-2P**, N-[4-[2-[4-(2-Amino-2-iminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide **737824-92-9P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylthio)benzyl]thiazol-2-yl]acetamide **737825-09-1P**, N-[4-[2-[4-[(Aminooxy)methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide **737825-15-9P**, N-[4-[2-[4-[[Amino(imino)methyl]amino]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride **737825-19-3P**, Methyl 4-[[2-(acetylamino)-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoate hydrochloride **737825-30-8P**, 4-[[2-(Acetylamino)-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethylbenzamide hydrochloride **737825-35-3P**, 4-[[2-(Acetylamino)-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methylbenzamide hydrochloride **737825-38-6P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-[(dimethylamino)methyl]thiazol-2-yl]acetamide dihydrochloride **737825-42-2P**, N-[5-[(4-Acetyl-1-piperazinyl)methyl]-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide dihydrochloride **737825-45-5P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)-1-piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride **737825-49-9P**, N-[4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-5-(4-thiomorpholinylmethyl)thiazol-2-yl]acetamide dihydrochloride **737825-52-4P**, 2-(Acetylamino)-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]thiazole-5-carboxamide hydrochloride **737825-56-8P**, 2-(Acetylamino)-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]thiazole-5-carboxamide hydrochloride **737825-60-4P**, 2-(Acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]thiazole-5-carboxamide hydrochloride **737825-64-8P**, 2-(Acetylamino)-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]thiazole-5-carboxamide hydrochloride **737825-68-2P**, 2-(Acetylamino)-4-[2-[4-[Amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-N-methylthiazole-5-carboxamide hydrochloride **737825-70-6P**,

2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-[benzyl(methyl)amino]-3-oxopropyl]thiazole-5-carboxamide hydrochloride **737825-72-8P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-oxobutyl]thiazole-5-carboxamide hydrochloride **737825-74-0P**, (2R)-1-[[2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide hydrochloride **737825-76-2P**, (2S)-1-[[2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide hydrochloride **737825-78-4P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-(methylsulfonyl)ethyl]thiazole-5-carboxamide hydrochloride **737825-80-8P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-pyridinylmethyl)thiazole-5-carboxamide dihydrochloride **737825-82-0P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-(3-pyridinylmethyl)thiazole-5-carboxamide dihydrochloride **737825-84-2P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-[(2-phenylacetyl)amino]ethyl]thiazole-5-carboxamide hydrochloride **737825-86-4P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-oxopentyl]thiazole-5-carboxamide hydrochloride **737825-88-6P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(benzylamino)-3-oxopropyl]thiazole-5-carboxamide hydrochloride **737825-90-0P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]thiazole-5-carboxamide hydrochloride **737825-92-2P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(4-morpholinyl)propyl]thiazole-5-carboxamide dihydrochloride **737825-94-4P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]thiazole-5-carboxamide hydrochloride **737825-96-6P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-hexylthiazole-5-carboxamide hydrochloride **737825-98-8P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-oxo-4-(1-piperidinyl)butyl]thiazole-5-carboxamide hydrochloride **737826-00-5P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-oxobutyl]thiazole-5-carboxamide hydrochloride **737826-02-7P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(methylsulfonyl)phenyl]thiazole-5-carboxamide hydrochloride **737826-05-0P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]thiazole-5-carboxamide hydrochloride **737826-07-2P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-1-benzyl-2-(dimethylamino)-2-oxoethyl]thiazole-5-carboxamide hydrochloride **737826-09-4P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]thiazole-5-carboxamide hydrochloride **737826-11-8P**, 2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]-N-[(1S,2S)-1-[(dimethylamino)carbonyl]-2-hydroxypropyl]thiazole-5-carboxamide hydrochloride **737826-13-0P**, (2S)-2-[[2-(Acetylamino)-4-[2-[4-[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]amino]-N,N-dimethylpentanediamide hydrochloride **737826-15-2P**, N-[4-[2-[4-[[(Imino)(methylamino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737826-16-3P**,


(2S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N,N-dimethyl-2-pyrrolidinecarboxamide dihydrochloride **737826-22-1P**, 3-[[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl](methyl)amino]-N,N-dimethylpropanamide dihydrochloride **737826-27-6P**, 4-[2-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]ethyl]-N,N-dimethylbenzamide hydrochloride **737826-33-4P**, 4-[2-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]ethyl]-N-methylbenzamide hydrochloride **737826-36-7P**, Methyl N-[4-[2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]phenyl]carbamate hydrochloride **737826-39-0P** **737826-42-5P**, 4-[2-[2-(Acetylamino)-5-[4-(methylsulfonyl)benzyl]thiazol-4-yl]ethyl]-N-[amino(imino)methyl]benzamide **737826-43-6P**, tert-Butyl [2-[4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl]amino]-2-oxoethyl]carbamate **737826-44-7P**, N-[4-[2-[2-(Acetylamino)-5-[4-(methylsulfonyl)benzyl]thiazol-4-yl]ethyl]phenyl]-2-aminoacetamide hydrochloride **737826-48-1P**, N-[4-[2-[4-[2-[4-[[amino(imino)methyl]amino]ethyl]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride **737826-59-4P**, N-[4-[2-[4-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[3-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride **737826-71-0P**, N-[4-[2-[4-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[1,1-dioxido-4-thiomorpholinyl]methyl]thiazol-2-yl]acetamide dihydrochloride **737826-74-3P**, N-[4-[2-[4-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-(4-morpholinylmethyl)thiazol-2-yl]acetamide dihydrochloride **737826-77-6P**, N-[4-[2-[4-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[3-oxo-1-piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride **737826-80-1P**, 4-[2-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N,N-dimethyl-1-piperazinecarboxamide dihydrochloride **737826-86-7P**, N-[4-[2-[4-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride **737826-88-9P**, N-[4-[2-[4-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride **737826-90-3P**, N-[4-[2-[4-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[4-[4-(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]thiazol-2-yl]acetamide trihydrochloride **737826-92-5P**, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]-N,N-dimethylpropanamide hydrochloride **737826-98-1P**, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]-N-methylpropanamide hydrochloride **737827-00-8P**, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]propanamide hydrochloride **737827-02-0P**, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N,N-dimethyl-4-piperidinecarboxamide dihydrochloride **737827-05-3P**, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N-methyl-4-piperidinecarboxamide dihydrochloride **737827-07-5P**, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-4-piperidinecarboxamide dihydrochloride **737827-09-7P**, (3R)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N,N-dimethyl-3-piperidinecarboxamide dihydrochloride **737827-14-4P**, (3R)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N-methyl-3-piperidinecarboxamide dihydrochloride **737827-16-6P**, (3S)-1-[[2-(Acetylamino)-4-[2-[4-

[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N,N-dimethyl-3-piperidinecarboxamide dihydrochloride **737827-21-3P**,
 (3S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N-methyl-3-piperidinecarboxamide dihydrochloride **737827-23-5P**, N-[4-[2-(2-Amino-1H-benzimidazol-6-yl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737827-26-8P**,
 N-[4-[2-(2-Amino-1H-benzimidazol-6-yl)ethyl]thiazol-2-yl]acetamide **737827-29-1P**, N-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl)methyl]-N-methylacetamide hydrochloride **737827-34-8P**, N-[4-[2-[4-[(2-Aminoethyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide dihydrochloride **737827-42-8P**, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride **737827-47-3P**, N-[4-[2-[4-[2-[4-[[Amino(imino)methyl]amino]ethyl]phenyl]ethyl]thiazol-2-yl]acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(VAP-1 inhibitor; preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)


RN 183365-33-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737822-86-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737822-89-8 CAPLUS

CN Acetamide, N-[4-[(1E)-2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/764,529




RN 737822-94-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737823-04-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-05-1 CAPLUS

CN Acetamide, N-[4-[2-[4-(aminoiminomethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737823-09-5 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetamino)-4-thiazolyl]ethyl]phenyl]-2-[(aminoiminomethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737823-29-9 CAPLUS


CN Acetamide, N-[4-[2-[3-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-34-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-bromo-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737823-41-5 CAPLUS


CN Acetamide, N-[4-[2-[4-[[(methyleamino)oxy]methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737823-47-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-48-2 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-chloro-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-50-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[[[aminoiminomethyl]amino]methyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/764,529

RN 737823-52-8 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-(acetamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-, ethyl ester, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 737823-55-1 CAPLUS


CN Acetamide, N-[4-[2-[4-[(ethylamino)iminomethyl]amino]phenyl]ethyl]-2-
thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-67-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[4-
(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX
NAME)


10/764,529



● HCl

RN 737823-78-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 737823-84-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-phenyl-, monohydrochloride (9CI)
(CA INDEX NAME)


10/764,529



● HCl

RN 737823-88-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737823-92-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737823-96-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-nitrophenyl)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-00-9 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(methylsulfonyl)phenyl]methyl
]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737824-05-4 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[[4-(trifluoromethyl)phenyl]methy
l]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 737824-09-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-3-pyridinyl-, dihydrochloride
(9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737824-13-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(4-phenoxyphenyl)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-15-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[2-(acetamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester
(9CI) (CA INDEX NAME)

10/764,529



RN 737824-17-8 CAPLUS


CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)carbonyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-19-0 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737824-21-4 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylcarbonyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 737824-23-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-25-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl
ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-27-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-30-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-32-7 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



● HCl


RN 737824-34-9 CAPLUS
CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737824-40-7 CAPLUS
CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(phenylmethyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737824-54-3 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-56-5 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737824-57-6 CAPLUS


CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-60-1 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(ethylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737824-76-9 CAPLUS


CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-82-7 CAPLUS


CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-83-8 CAPLUS


CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-84-9 CAPLUS


CN Acetamide, N-[4-[2-[4-[(1-iminoethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737824-85-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(iminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-
(9CI) (CA INDEX NAME)




RN 737824-86-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[(hydrazinoiminomethyl)amino]phenyl]ethyl]-2-
thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-87-2 CAPLUS


CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]-
(9CI) (CA INDEX NAME)



10/764,529


RN 737824-92-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-09-1 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminooxy)methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-15-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[[[(aminoiminomethyl)amino]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-19-3 CAPLUS

CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-30-8 CAPLUS


CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



● HCl


RN 737825-35-3 CAPLUS
CN Benzamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-38-6 CAPLUS
CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737825-42-2 CAPLUS

CN Acetamide, N-[5-[[4-(4-acetyl-1-piperazinyl)methyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737825-45-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl


RN 737825-49-9 CAPLUS
 CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 737825-52-4 CAPLUS
 CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-56-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-60-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-64-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-68-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-70-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-[methyl(phenylmethyl)amino]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-72-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(dimethylamino)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529




● HCl

RN 737825-74-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737825-76-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-N,N-dimethyl-, monohydrochloride, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



● HCl

RN 737825-78-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737825-80-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



●2 HCl

RN 737825-82-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-(3-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 737825-84-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[2-[(phenylacetyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737825-86-4 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-oxopentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-88-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-oxo-3-[(phenylmethyl)amino]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/764,529

RN 737825-90-0 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-92-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(4-morpholinyl)propyl]-,
dihydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 2-A


● 2 HCl

RN 737825-94-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-

10/764,529


, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737825-96-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-hexyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 737825-98-8 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-oxo-4-(1-piperidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737826-00-5 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(4-morpholinyl)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 737826-02-7 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[4-(4-methylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



RN 737826-05-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737826-07-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-2-oxo-1-(phenylmethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/764,529




● HCl

RN 737826-09-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737826-11-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N-[(1S,2S)-1-[(dimethylamino)carbonyl]-2-hydroxypropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/764,529




● HCl

RN 737826-13-0 CAPLUS

CN Pentanediamide, 2-[[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]carbonyl]amino]-N,N-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 737826-15-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[[imino(methylamino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


10/764,529



RN 737826-16-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 737826-22-1 CAPLUS

CN Propanamide, 3-[[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-27-6 CAPLUS

CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737826-33-4 CAPLUS


CN Benzamide, 4-[2-[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



RN 737826-36-7 CAPLUS


CN Carbamic acid, [4-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 737826-39-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]phenyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-42-5 CAPLUS


CN Benzamide, 4-[[2-[[2-(acetylamino)-5-[[4-(methanesulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-N-(aminoiminomethyl)phenyl]methyl]-N-(4-aminophenyl)-2-oxoethyl]benzamide (9CI) (CA INDEX NAME)



RN 737826-43-6 CAPLUS


CN Carbamic acid, [2-[[4-[[2-[[2-(acetylamino)-5-[[4-(methanesulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-1,1-dimethylethyl]ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-44-7 CAPLUS

CN Acetamide, N-[4-[2-[2-(acetamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737826-48-1 CAPLUS

CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl

RN 737826-59-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737826-71-0 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-74-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-(4-morpholinylmethyl)-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737826-77-6 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737826-80-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 737826-86-7 CAPLUS
CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



RN 737826-88-9 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 737826-90-3 CAPLUS

10/764,529

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-2-thiazolyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Me

● 3 HCl


RN 737826-92-5 CAPLUS
CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



● HCl


RN 737826-98-1 CAPLUS
CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 737827-00-8 CAPLUS
CN 5-Thiazolepropanamide, 2-(acetylamino)-4-[2-[4-
[(aminoiminomethyl)amino]phenyl]ethyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

10/764,529



● HCl


RN 737827-02-0 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 737827-05-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737827-07-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 737827-09-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

10/764,529

Absolute stereochemistry.




●2 HCl

RN 737827-14-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 737827-16-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

10/764,529

Absolute stereochemistry.




●2 HCl

RN 737827-21-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, dihydrochloride, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 737827-23-5 CAPLUS


CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)

10/764,529




RN 737827-26-8 CAPLUS

CN Acetamide, N-[4-[2-(2-amino-1H-benzimidazol-5-yl)ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737827-29-1 CAPLUS

CN Acetamide, N-[[2-(acetylamino)-4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-thiazolyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737827-34-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[(2-aminoethyl)amino]phenyl]ethyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)


10/764,529



● 2 HCl

RN 737827-42-8 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737827-47-3 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



IT **183365-28-8P**, N-[4-[(E)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide **183365-29-9P**, N-[4-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]acetamide **737822-88-7P**, N-[4-[(Z)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide **737822-90-1P**, N-[4-[(E)-2-(4-Aminophenyl)ethenyl]thiazol-2-yl]acetamide **737822-92-3P**, N-[4-[2-[4-[[(Benzoylamino)carbonothioyl]amino]phenyl

1]ethyl]thiazol-2-yl]acetamide **737822-93-4P**,
 N-[4-[2-[4-[(Aminocarbonothioyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide
737823-06-2P, N-[4-[(Z)-2-(4-Cyanophenyl)ethenyl]thiazol-2-yl]acetamide
737823-07-3P, N-[4-[2-(4-Cyanophenyl)ethyl]thiazol-2-yl]acetamide
737823-08-4P, 4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]benzenecarboximidic acid ethyl ester hydrochloride
737823-10-8P, tert-Butyl [2-[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]amino]-2-oxoethyl]carbamate **737823-11-9P**,
 N-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]-2-aminoacetamide
 hydrochloride **737823-20-0P**, N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]thiazol-2-yl]acetamide **737823-21-1P**,
 N-[4-[2-[4-(Bromomethyl)phenyl]ethyl]thiazol-2-yl]acetamide
737823-22-2P, N-[4-[2-[4-[(Diformylamino)methyl]phenyl]ethyl]thiazol-2-yl]acetamide
737823-30-2P, N-[4-[2-(3-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide **737823-31-3P**,
 N-[4-[2-(3-Aminophenyl)ethyl]thiazol-2-yl]acetamide **737823-32-4P**
737823-33-5P 737823-35-7P 737823-36-8P
737823-38-0P, Methyl 4-[(Z)-2-[2-(acetylamino)thiazol-4-yl]ethenyl]benzoate
737823-39-1P, Methyl 4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]benzoate **737823-40-4P**,
 N-[4-[2-[4-[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)oxy]methyl]phenyl]ethyl]thiazol-2-yl]acetamide **737823-49-3P**
737823-51-7P 737823-53-9P, Ethyl 2-(acetylamino)-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazole-5-carboxylate **737823-54-0P**,
 Ethyl 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxylate
737823-74-4P, N-[5-[4-(Methylthio)phenyl]-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide
737823-75-5P, N-[5-[4-(Methylsulfonyl)phenyl]-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide
737823-76-6P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide **737823-77-7P**
737823-79-9P, Ethyl 2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazole-5-carboxylate
737823-80-2P, 2-(Acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazole-5-carboxylic acid
737823-81-3P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737823-82-4P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-methylthiazole-5-carboxamide **737823-83-5P 737823-85-7P**,
 tert-Butyl [4-[2-[2-(acetylamino)-5-(anilino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737823-86-8P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-phenylthiazole-5-carboxamide **737823-87-9P**
737823-89-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737823-90-4P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N,N-dimethylthiazole-5-carboxamide
737823-91-5P 737823-93-7P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(benzylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737823-94-8P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-benzylthiazole-5-carboxamide
737823-95-9P
737823-97-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-(nitrobenzyl)amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737823-98-2P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-(4-nitrobenzyl)thiazole-5-carboxamide
737823-99-3P
737824-01-0P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[4-(methylthio)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737824-02-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate
737824-03-2P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[4-(methylsulfonyl)benzyl]thiazole-5-carboxamide **737824-04-3P**

737824-06-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl] carbamate **737824-07-6P**, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[4-(trifluoromethyl)benzyl]thiazole-5-carboxamide
737824-08-7P 737824-10-1P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxylic acid **737824-11-2P**
737824-12-3P 737824-14-5P 737824-16-7P
737824-18-9P 737824-20-3P 737824-22-5P
737824-24-7P 737824-26-9P 737824-28-1P
737824-29-2P 737824-31-6P 737824-33-8P
737824-37-2P 737824-38-3P, N-[4-[2-(4-Aminophenyl)ethyl]-5-phenylthiazol-2-yl]acetamide **737824-39-4P 737824-43-0P**
737824-44-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-benzylthiazol-2-yl]acetamide **737824-45-2P 737824-52-1P**
737824-53-2P 737824-55-4P 737824-58-7P,
N-[4-[2-[4-[(Aminocarbonothioyl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-59-8P**
737824-67-8P 737824-68-9P 737824-69-0P
737824-71-4P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl] carbamate
737824-77-0P, Methyl 4-[(Z)-2-[2-(acetylamino)-5-[[4-(methylthio)phenyl]methyl]thiazol-4-yl]ethenyl]benzoate
737824-78-1P, Methyl 4-[(Z)-2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethenyl]benzoate
737824-79-2P, Methyl 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]benzoate
737824-80-5P, N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-81-6P**,
N-[4-[2-[4-(Chloromethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-88-3P**, N-[4-[2-[4-(Chloromethyl)phenyl]ethyl]thiazol-2-yl]acetamide **737824-89-4P**,
N-[4-[2-[4-(Cyanomethyl)phenyl]ethyl]thiazol-2-yl]acetamide
737824-90-7P, 2-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]ethanimidic acid methyl ester hydrochloride
737824-91-8P, N-[4-[2-[4-(2-Amino-2-iminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride **737824-93-0P 737824-94-1P**
, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfinyl)benzyl]thiazol-2-yl]acetamide **737824-95-2P 737825-10-4P**, Methyl
4-[(E)-2-[2-(acetylamino)-5-[4-(methylthio)phenyl]thiazol-4-yl]ethenyl]benzoate **737825-11-5P**, Methyl 4-[(E)-2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]ethenyl]benzoate
737825-12-6P, Methyl 4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]ethyl]benzoate **737825-13-7P**,
N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide **737825-14-8P**, N-[4-[2-[4-[[1,3-Dioxo-1,3-dihydro-2H-isindol-2-yl]oxy]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide **737825-16-0P**,
N-[4-[2-[4-(Bromomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide **737825-17-1P**, N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide **737825-18-2P 737825-25-1P**,
N-[5-(4-Iodobenzyl)-4-[2-(4-nitrophenyl)vinyl]thiazol-2-yl]acetamide
737825-27-3P 737825-28-4P, Methyl 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]benzoate **737825-29-5P**
737825-31-9P, Methyl 4-[[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoate
737825-32-0P, 4-[[2-(Acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoic acid
737825-33-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-

[(dimethylamino) carbonyl] phenyl] methyl] thiazol-4-yl] ethyl] phenyl] carbamate
737825-34-2P 737825-36-4P, tert-Butyl
 [4-[2-[2-(acetylamino)-5-[[4-[(methylamino) carbonyl] phenyl] methyl] thiazol-4-yl] ethyl] phenyl] carbamate **737825-37-5P 737825-39-7P**
737825-40-0P, N-[4-[2-(4-Aminophenyl) ethyl]-5-
 [(dimethylamino) methyl] thiazol-2-yl] acetamide **737825-41-1P**
737825-43-3P 737825-44-4P 737825-46-6P
737825-48-8P 737825-50-2P 737825-51-3P
737825-53-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[2-(
 (dimethylamino)-2-oxoethyl] amino] carbonyl] thiazol-4-
 yl] ethyl] phenyl] carbamate **737825-54-6P**, 2-(Acetylamino)-4-[2-(4-
 aminophenyl) ethyl]-N-[2-(dimethylamino)-2-oxoethyl] thiazole-5-carboxamide
 hydrochloride **737825-55-7P 737825-57-9P**, tert-Butyl
 [4-[2-[2-(acetylamino)-5-[[3-(dimethylamino)-3-
 oxopropyl] amino] carbonyl] thiazol-4-yl] ethyl] phenyl] carbamate
737825-58-0P, 2-(Acetylamino)-4-[2-(4-aminophenyl) ethyl]-N-[3-
 (dimethylamino)-3-oxopropyl] thiazole-5-carboxamide hydrochloride
737825-59-1P 737825-61-5P, tert-Butyl
 [4-[2-[2-(acetylamino)-5-[[2-(acetylamino) ethyl] amino] carbonyl] thiazol-4-
 yl] ethyl] phenyl] carbamate **737825-62-6P**, 2-(Acetylamino)-N-[2-
 (acetylamino) ethyl]-4-[2-(4-aminophenyl) ethyl] thiazole-5-carboxamide
 hydrochloride **737825-63-7P 737825-65-9P**, tert-Butyl
 [4-[2-[2-(acetylamino)-5-[[2-[(methylsulfonyl) amino] ethyl] amino] carbonyl]
 thiazol-4-yl] ethyl] phenyl] carbamate **737825-66-0P**,
 2-(Acetylamino)-4-[2-(4-aminophenyl) ethyl]-N-[2-
 [(methylsulfonyl) amino] ethyl] thiazole-5-carboxamide hydrochloride
737825-67-1P 737825-69-3P 737825-71-7P
737825-73-9P 737825-75-1P 737825-77-3P
737825-79-5P 737825-81-9P 737825-83-1P
737825-85-3P 737825-87-5P 737825-89-7P
737825-91-1P 737825-93-3P 737825-95-5P
737825-97-7P 737825-99-9P 737826-01-6P
737826-03-8P 737826-04-9P 737826-06-1P
737826-08-3P 737826-10-7P 737826-12-9P
737826-14-1P 737826-17-4P, tert-Butyl
 [4-[2-[2-(acetylamino)-5-[[methoxy(methyl) amino] carbonyl] thiazol-4-
 yl] ethyl] phenyl] carbamate **737826-18-5P**, tert-Butyl
 [4-[2-[2-(acetylamino)-5-formylthiazol-4-yl] ethyl] phenyl] carbamate
737826-19-6P 737826-20-9P, (2S)-1-[2-(Acetylamino)-4-[2-
 (4-aminophenyl) ethyl] thiazol-5-yl] methyl]-N,N-dimethyl-2-
 pyrrolidinecarboxamide **737826-21-0P 737826-23-2P**,
 tert-Butyl [4-[2-[2-(acetylamino)-5-[[3-(N,N-dimethylamino)-3-
 oxopropyl] amino] methyl] thiazol-4-yl] ethyl] phenyl] carbamate
737826-24-3P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[3-(N,N-
 dimethylamino)-3-oxopropyl] (methyl) amino] methyl] thiazol-4-
 yl] ethyl] phenyl] carbamate **737826-25-4P**, 3-[[2-(Acetylamino)-4-
 [2-(4-aminophenyl) ethyl] thiazol-5-yl] methyl] (methyl) amino]-N,N-
 dimethylpropanamide **737826-26-5P 737826-28-7P**, Methyl
 4-[2-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl) amino] phenyl] ethyl] thi-
 azol-5-yl] vinyl] benzoate **737826-29-8P**, Methyl
 4-[2-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl) amino] phenyl] ethyl] thi-
 azol-5-yl] ethyl] benzoate **737826-30-1P**, 4-[2-[2-(Acetylamino)-4-
 [2-[4-[(tert-butoxycarbonyl) amino] phenyl] ethyl] thiazol-5-yl] ethyl] benzoic
 acid **737826-31-2P**, tert-Butyl [4-[2-[2-(acetylamino)-5-[2-[4-
 [(methylamino) carbonyl] phenyl] ethyl] thiazol-4-yl] ethyl] phenyl] carbamate
737826-32-3P 737826-34-5P, tert-Butyl
 [4-[2-[2-(Acetylamino)-5-[2-[4-[(dimethylamino) carbonyl] phenyl] ethyl] thiaz-
 ol-4-yl] ethyl] phenyl] carbamate **737826-35-6P 737826-37-8P**
 , Methyl N-[4-[2-(acetylamino)-4-[2-[4-[(tert-

butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl)methyl]phenyl]carbamate
737826-38-9P 737826-40-3P, Ethyl 1-[[2-(acetylamino)-4-
 [(Z)-2-(4-nitrophenyl)ethenyl]thiazol-5-yl)methyl]-4-piperidinecarboxylate
737826-41-4P 737826-47-0P, tert-Butyl
 [2-[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]ethyl]carbamate
737826-49-2P 737826-68-5P 737826-69-6P,
 N-[4-[2-(4-Aminophenyl)ethyl]-5-[3-(methylsulfonyl)benzyl]thiazol-2-
 yl]acetamide **737826-70-9P 737826-72-1P**
737826-73-2P 737826-75-4P 737826-76-5P
737826-78-7P 737826-79-8P 737826-81-2P,
 9H-Fluoren-9-ylmethyl 4-[[2-(acetylamino)-4-[(Z)-2-(4-
 nitrophenyl)ethenyl]thiazol-5-yl)methyl]-1-piperazinecarboxylate
737826-82-3P, 9H-Fluoren-9-ylmethyl 4-[[2-(acetylamino)-4-[2-(4-
 aminophenyl)ethyl]thiazol-5-yl)methyl]-1-piperazinecarboxylate
737826-83-4P 737826-84-5P 737826-85-6P
737826-87-8P 737826-89-0P 737826-91-4P
737826-93-6P, Ethyl 3-[2-(acetylamino)-4-[2-[4-[(tert-
 butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]-2-propenoate
737826-94-7P, Ethyl 3-[2-(acetylamino)-4-[2-[4-[(tert-
 butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]propanoate
737826-95-8P 737826-96-9P 737826-97-0P
737826-99-2P 737827-01-9P 737827-03-1P
737827-04-2P 737827-06-4P 737827-08-6P
737827-10-0P 737827-11-1P 737827-12-2P
737827-13-3P 737827-15-5P 737827-17-7P
737827-18-8P 737827-19-9P 737827-20-2P
737827-22-4P 737827-24-6P 737827-25-7P,
 N-[4-[2-(3,4-Diaminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-
 yl]acetamide **737827-27-9P 737827-28-0P**,
 N-[4-[2-(3,4-Diaminophenyl)ethyl]thiazol-2-yl]acetamide
737827-30-4P 737827-31-5P 737827-32-6P,
 N-[[2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl)methyl]-N-
 methylacetamide **737827-33-7P 737827-35-9P**, tert-Butyl
 [2-[[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]amino]ethyl]carbamate
737827-43-9P, tert-Butyl N-[4-[2-[2-(acetylamino)-5-[(E)-2-[4-
 (methylsulfonyl)phenyl]ethenyl]thiazol-4-yl]ethyl]phenyl]carbamate
737827-44-0P, tert-Butyl N-[4-[2-[2-(acetylamino)-5-[2-[4-
 (methylsulfonyl)phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate
737827-45-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[2-[4-
 (methylsulfonyl)phenyl]ethyl]thiazol-2-yl]acetamide **737827-46-2P**
740816-44-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of thiazole derivs. as VAP-1 inhibitors for
 treatment of macular edema and other VAP-1 associated diseases)

RN 183365-28-8 CAPLUS

CN Acetamide, N-[4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA
 INDEX NAME)


Double bond geometry as shown.



10/764,529

RN 183365-29-9 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737822-88-7 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 737822-90-1 CAPLUS


CN Acetamide, N-[4-[(1E)-2-(4-aminophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737822-92-3 CAPLUS


CN Benzamide, N-[[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)



10/764,529

RN 737822-93-4 CAPLUS


CN Acetamide, N-[4-[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737823-06-2 CAPLUS


CN Acetamide, N-[4-[(1Z)-2-(4-cyanophenyl)ethenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737823-07-3 CAPLUS


CN Acetamide, N-[4-[2-(4-cyanophenyl)ethyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737823-08-4 CAPLUS

CN Benzenecarboximide, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl


RN 737823-10-8 CAPLUS

CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737823-11-9 CAPLUS


CN Acetamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-2-amino-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737823-20-0 CAPLUS


CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-21-1 CAPLUS


10/764,529

CN Acetamide, N-[4-[2-[4-(bromomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737823-22-2 CAPLUS

CN Acetamide, N-[4-[2-[4-[(diformylamino)methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737823-30-2 CAPLUS

CN Acetamide, N-[4-[2-(3-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-31-3 CAPLUS


CN Acetamide, N-[4-[2-(3-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-32-4 CAPLUS


CN Carbamic acid, [[3-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737823-33-5 CAPLUS

CN Carbamic acid, [[3-[2-[2-(acetylamino)-5-bromo-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737823-35-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-36-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-bromo-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737823-38-0 CAPLUS

CN Benzoic acid, 4-[(1Z)-2-[2-(acetylamino)-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)


10/764,529

Double bond geometry as shown.




RN 737823-39-1 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetylthiazol-4-yl)ethyl]-, methyl ester
(9CI) (CA INDEX NAME)




RN 737823-40-4 CAPLUS

CN Acetamide, N-[4-[2-[4-[[[1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl]oxy]methyl]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-49-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylthiazol-5-chloro-4-thiazolyl)ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)



10/764,529

RN 737823-51-7 CAPLUS


CN Carbamic acid, [[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]methyl]carbamimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-53-9 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[(1E)-2-(4-nitrophenyl)ethenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737823-54-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 737823-74-4 CAPLUS

CN Acetamide, N-[5-[4-(methylthio)phenyl]-4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



RN 737823-75-5 CAPLUS


CN Acetamide, N-[5-[4-(methylsulfonyl)phenyl]-4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737823-76-6 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737823-77-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737823-79-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 737823-80-2 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 737823-81-3 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529




RN 737823-82-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-methyl-
(9CI) (CA INDEX NAME)



RN 737823-83-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)



RN 737823-85-7 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(phenylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529




RN 737823-86-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-phenyl-
(9CI) (CA INDEX NAME)



RN 737823-87-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(phenylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)



RN 737823-89-1 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529




RN 737823-90-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 737823-91-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-93-7 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(phenylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529




RN 737823-94-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 737823-95-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(phenylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737823-97-1 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737823-98-2 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 737823-99-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-01-0 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[4-(methylthio)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737824-02-1 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529




RN 737824-03-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[[4-(methylsulfonyl)phenyl]methyl]-(9CI) (CA INDEX NAME)




RN 737824-04-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737824-06-5 CAPLUS
 CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-07-6 CAPLUS


CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 737824-08-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737824-10-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 737824-11-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[bis[[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 737824-12-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(3-pyridinylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-14-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-16-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-[4-[[bis[[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-18-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(4-acetyl-1-piperazinyl)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-20-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-22-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-thiomorpholinylcarbonyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-24-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(1,1-dioxido-4-thiomorpholinyl)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-26-9 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 737824-28-1 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]carbonyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-29-2 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-31-6 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-33-8 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-37-2 CAPLUS


CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737824-38-3 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737824-39-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-phenyl-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-43-0 CAPLUS


CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-(phenylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-44-1 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-(phenylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737824-45-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(phenylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737824-52-1 CAPLUS


CN Acetamide, N-[5-[[4-(methylthio)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-53-2 CAPLUS


CN Acetamide, N-[5-[[4-(methylsulfonyl)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-55-4 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737824-58-7 CAPLUS

CN Acetamide, N-[4-[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737824-59-8 CAPLUS
CN Carbamimidothioic acid, [4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, methyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 737824-67-8 CAPLUS
CN Acetamide, N-[5-[[4-(ethylthio)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737824-68-9 CAPLUS


CN Acetamide, N-[5-[[4-(ethylsulfonyl)phenyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-69-0 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(ethylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737824-71-4 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 737824-77-0 CAPLUS

CN Benzoic acid, 4-[(1Z)-2-[2-(acetamino)-5-[[4-(methylthio)phenyl]methyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



RN 737824-78-1 CAPLUS


CN Benzoic acid, 4-[(1Z)-2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 737824-79-2 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



10/764,529


RN 737824-80-5 CAPLUS

CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737824-81-6 CAPLUS

CN Acetamide, N-[4-[2-[4-(chloromethyl)phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-88-3 CAPLUS

CN Acetamide, N-[4-[2-[4-(chloromethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737824-89-4 CAPLUS

CN Acetamide, N-[4-[2-[4-(cyanomethyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA


10/764,529

INDEX NAME)



RN 737824-90-7 CAPLUS


CN Benzenethanimidic acid, 4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 737824-91-8 CAPLUS

CN Acetamide, N-[4-[2-[4-(2-amino-2-iminoethyl)phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 737824-93-0 CAPLUS

CN Acetamide, N-[5-[[4-(methylsulfinyl)phenyl]methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/764,529



RN 737824-94-1 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfinyl)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737824-95-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfinyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/764,529



RN 737825-10-4 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[2-(acetylamino)-5-[4-(methylthio)phenyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 737825-11-5 CAPLUS

CN Benzoic acid, 4-[(1E)-2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/764,529




RN 737825-12-6 CAPLUS

CN Benzoic acid, 4-[2-[2-(acetamino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 737825-13-7 CAPLUS


CN Acetamide, N-[4-[2-[4-(hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



10/764,529


RN 737825-14-8 CAPLUS

CN Acetamide, N-[4-[2-[4-[[[1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy)methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)




RN 737825-16-0 CAPLUS

CN Acetamide, N-[4-[2-[4-(bromomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737825-17-1 CAPLUS


CN Acetamide, N-[4-[2-[4-(aminomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



10/764,529


RN 737825-18-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetyl-amino)-5-[4-(methylsulfonyl)phenyl]-4-thiazolyl]ethyl]phenyl]methyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-25-1 CAPLUS


CN Acetamide, N-[5-[(4-iodophenyl)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-27-3 CAPLUS


CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737825-28-4 CAPLUS


CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 737825-29-5 CAPLUS


CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[bis[[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737825-31-9 CAPLUS


CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 737825-32-0 CAPLUS


CN Benzoic acid, 4-[[2-(acetylamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737825-33-1 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737825-34-2 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737825-36-4 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737825-37-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737825-39-7 CAPLUS

CN Acetamide, N-[5-[(dimethylamino)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-40-0 CAPLUS


CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[(dimethylamino)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-41-1 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(dimethylamino)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737825-43-3 CAPLUS

CN Acetamide, N-[5-[(4-acetyl-1-piperazinyl)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-44-4 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(4-acetyl-1-piperazinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



10/764,529


RN 737825-46-6 CAPLUS

CN Acetamide, N-[5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737825-48-8 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737825-50-2 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-(4-thiomorpholinylmethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/764,529



● HCl


RN 737825-55-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-57-9 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737825-58-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl


RN 737825-59-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-61-5 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[2-(acetylamino)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737825-62-6 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-(4-aminophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● HCl


RN 737825-63-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetamino)-5-[[[2-(acetamino)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-65-9 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetamino)-5-[[[2-[(methylsulfonyl)amino]ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737825-66-0 CAPLUS

CN 5-Thiazolecarboxamide, 2-(acetamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/764,529



● ·HCl


RN 737825-67-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-[(methylsulfonyl)amino]ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-69-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737825-71-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[3-[methyl(phenylmethyl)amino]-3-oxopropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-,


10/764,529

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-73-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(dimethylamino)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-75-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(dimethylamino)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/764,529

RN 737825-77-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[2-(dimethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 737825-79-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[2-(methylsulfonyl)ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-81-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-pyridinylmethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737825-83-1 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-pyridinylmethyl)amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-85-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[2-[(phenylacetyl)amino]ethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737825-87-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[5-(dimethylamino)-5-oxopentyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-89-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-oxo-3-[(phenylmethyl)amino]propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737825-91-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[6-(dimethylamino)-6-oxohexyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/764,529

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-93-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-(4-morpholinyl)propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-95-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737825-97-7 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(hexylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737825-99-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-oxo-4-(1-piperidinyl)butyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-01-6 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(4-morpholinyl)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-03-8 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(4-morpholinyl)-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-04-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-06-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[2-(dimethylamino)-1-methyl-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/764,529



RN 737826-08-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737826-10-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737826-12-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S,2S)-1-(hydroxymethyl)-2-oxoethyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529

[(dimethylamino)carbonyl]-2-hydroxypropyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737826-14-1 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(1S)-4-amino-1-[(dimethylamino)carbonyl]-4-oxobutyl]amino]carbonyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737826-17-4 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(methoxymethylamino)carbonyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-18-5 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetamido)-5-formyl-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-19-6 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetamido)-5-[[2-(dimethylamino)carbonyl]-1-pyrrolidinyl]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737826-20-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(acetamido)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



RN 737826-21-0 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(2S)-2-[(dimethylamino)carbonyl]-1-pyrrolidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 737826-23-2 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]amino]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-24-3 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]methyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/764,529




RN 737826-25-4 CAPLUS

CN Propanamide, 3-[[[2-(acetamido)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]methylamino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 737826-26-5 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetamido)-5-[[[3-(dimethylamino)-3-oxopropyl]methylamino]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-28-7 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetamido)-4-[2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethenyl]-, methyl ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-29-8 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetamino)-4-[2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 737826-30-1 CAPLUS


CN Benzoic acid, 4-[2-[2-(acetamino)-4-[2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]ethyl]- (9CI) (CA INDEX NAME)

10/764,529



RN 737826-31-2 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-32-3 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-34-5 CAPLUS


CN Carbamic acid, [4-[2-[2-(acetamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-35-6 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737826-37-8 CAPLUS


CN Carbamic acid, [4-[[2-(acetamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 737826-38-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetamido)-5-[[4-[(methoxycarbonyl)amino]phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


10/764,529



RN 737826-40-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 737826-41-4 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/764,529




RN 737826-47-0 CAPLUS

CN Carbamic acid, [2-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737826-49-2 CAPLUS

CN Carbamic acid, [[2-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]ethyl]carbamimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737826-68-5 CAPLUS

CN Acetamide, N-[5-[3-(methylsulfonyl)phenyl]methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/764,529




RN 737826-69-6 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[[3-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



RN 737826-70-9 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[3-(methylsulfonyl)phenyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



10/764,529


RN 737826-72-1 CAPLUS

CN Acetamide, N-[5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737826-73-2 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-75-4 CAPLUS


CN Acetamide, N-[5-(4-morpholinylmethyl)-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 737826-76-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(4-morpholinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-78-7 CAPLUS


CN Acetamide, N-[4-[2-(4-nitrophenyl)ethenyl]-5-[(3-oxo-1-piperazinyl)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



10/764,529

RN 737826-79-8 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(3-oxo-1-piperazinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-81-2 CAPLUS



CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 737826-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




RN 737826-83-4 CAPLUS
 CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(9H-fluoren-9-ylmethoxy)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbamimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737826-84-5 CAPLUS
 CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(1-piperazinylmethyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester
 (9CI) (CA INDEX NAME)

10/764,529



RN 737826-85-6 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737826-87-8 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529





RN 737826-89-0 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737826-91-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737826-93-6 CAPLUS
 CN 2-Propenoic acid, 3-[2-(acetamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-5-thiazolyl]-, ethyl ester
 (9CI) (CA INDEX NAME)



RN 737826-94-7 CAPLUS


10/764,529

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 737826-95-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[bis[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 737826-96-9 CAPLUS


CN 5-Thiazolepropanoic acid, 2-(acetylamino)-4-[2-[4-[[bis[[1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 737826-97-0 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[3-(dimethylamino)-3-oxopropyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529




RN 737826-99-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[3-(methylamino)-3-oxopropyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737827-01-9 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-(3-amino-3-oxopropyl)-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737827-03-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[2-(acetlamino)-4-[2-[4-[[bis[[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-


10/764,529

thiazolyl)methyl]- (9CI) (CA INDEX NAME)



RN 737827-04-2 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]-1-piperidinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737827-06-4 CAPLUS


CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]-1-piperidinyl)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

10/764,529



RN 737827-08-6 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[4-(aminocarbonyl)-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 737827-10-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


10/764,529



RN 737827-11-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy) carbonyl] amino] methylene] amino] phenyl] ethyl]-5-thiazolyl]methyl]-, ethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737827-12-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[[(1,1-dimethylethoxy) carbonyl] amino] methylene] amino] phenyl] ethyl]-5-thiazolyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



RN 737827-13-3 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3R)-3-[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737827-15-5 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[(3R)-3-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



RN 737827-17-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 737827-18-8 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



RN 737827-19-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[2-(acetylamino)-4-[2-[4-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]ethyl]-5-thiazolyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737827-20-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[[[(3S)-3-[(dimethylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/764,529



RN 737827-22-4 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetamino)-5-[[[(3S)-3-[(methylamino)carbonyl]-1-piperidinyl]methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737827-24-6 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(3,4-dinitrophenyl)ethenyl]-5-[[4-(methylthio)phenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/764,529



RN 737827-25-7 CAPLUS


CN Acetamide, N-[4-[2-(3,4-diaminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl] - (9CI) (CA INDEX NAME)



RN 737827-27-9 CAPLUS

CN Acetamide, N-[4-[(1Z)-2-(3,4-dinitrophenyl)ethenyl]-2-thiazolyl] - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



10/764,529


RN 737827-28-0 CAPLUS

CN Acetamide, N-[4-[2-(3,4-diaminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737827-30-4 CAPLUS


CN Acetamide, N-[5-[(methylamino)methyl]-4-[2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 737827-31-5 CAPLUS


CN Acetamide, N-[[2-(acetylamino)-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-5-thiazolyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737827-32-6 CAPLUS


CN Acetamide, N-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-5-thiazolyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



10/764,529


RN 737827-33-7 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[(acetylmethylamino)methyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 737827-35-9 CAPLUS


CN Carbamic acid, [2-[[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737827-43-9 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[(1E)-2-[4-(methylsulfonyl)phenyl]ethenyl]-4-thiazolyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 737827-44-0 CAPLUS

CN Carbamic acid, [4-[2-[2-(acetylamino)-5-[2-[4-


10/764,529

(methylsulfonyl)phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 737827-45-1 CAPLUS

CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 737827-46-2 CAPLUS

CN Carbamic acid, [[4-[2-[2-(acetylamino)-5-[2-[4-(methylsulfonyl)phenyl]ethyl]-4-thiazolyl]ethyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 740816-44-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-(acetylamino)-4-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino][[(1,1-dimethylethoxy)carbonyl]imino]methyl]amino]phenyl]ethyl]-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)



IT 737825-26-2


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)


RN 737825-26-2 CAPLUS

CN Acetamide, N-[5-[(4-iodophenyl)methyl]-4-[(1Z)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI




II

AB Title compds. of formula R_1NHXYZ [I; wherein R_1 = acyl; X = a bivalent (un)substituted thiazole; Y = a bond, alkylene, alkenylene, COHN; Z = 2-aminobenzimidazolyl, $C_6H_4-R_2$; R_2 = ABDE; A = a bond, alkylene, NH, SO_2 ; B = a bond, alkylene, CO, O; D = a bond, alkylene, NH, CH_2NH ; E = (un)protected amino, $N=CH_2$, dihydrothiazol-2-yl, dihydroimidazol-2-yl, $C(=NH)R_3$; R_3 = H, alkyl(thio), NHR_4 ; R_4 = H, NH_2 , alkyl; and pharmaceutically acceptable salts thereof] were prepared as vascular adhesion protein-1 (VAP-1) inhibitors. For example, cycloaddn. of 3-chloro-2-oxopropyl acetate and thiourea in EtOH gave (2-amino-1,3-thiazol-4-yl)methyl acetate•HCl, which was amidated with acetyl chloride using pyridine in CH_2Cl_2 . Deprotection of [2-(acetylamino)thiazol-4-yl]methyl acetate using K_2CO_3 in MeOH, followed by reaction of the resulting alc. with MnO_2 in MeOH/ $CHCl_3$ provided N-(4-formylthiazol-2-yl)acetamide. Coupling of the aldehyde with 1-(bromomethyl)-4-nitrobenzene in the presence of PPh_3 and t-BuOH in DMF gave N-[4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide, which was reduced to the amine with Pd/C in MeOH/THF/AcOH. Finally, coupling of the amine with cyanamide in the presence of HCl in EtOH/EtOAc afforded II. The latter inhibited VAP-1 enzyme (SSAO) activity in both human and rat plasma (IC_{50} = 0.15 μM and 0.012 μM , resp.), but not the enzyme activities of other amine oxidases (IC_{50} >100 μM), such as human platelet monoamine oxidase (MAO) and cloned diamine oxidase (DAO, histaminase). Treatment of diabetic rats daily with II (10 mg/kg/ s.c. u.i.d.) improved their ocular permeability in comparison with the diabetic control group (vitreous/plasma ratio of fluorescein concns. = $5.39 \pm 0.73 \times 10^{-3}$ and $8.93 \pm 1.14 \times 10^{-3}$, resp.). Thus, I and their pharmaceutical compns. are useful for preventing or treating VAP-1 associated diseases, especially macular edema (no data).

L8 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:835624 CAPLUS
 DOCUMENT NUMBER: 139:6779

10/764,529

TITLE: Product class 17: thiazoles
AUTHOR(S): Kikelj, D.; Urleb, U.
CORPORATE SOURCE: Fac. Pharm., University Ljubljana, Slovenia
SOURCE: Science of Synthesis (2002), 11, 627-833
CODEN: SSCYJ9
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
IT 92061-29-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(review of preparation of thiazoles and reactions thereof)
RN 92061-29-5 CAPLUS
CN Acetamide, N-[4-[2-(4-cyanophenyl)ethenyl]-5-nitro-2-thiazolyl]- (9CI)
(CA INDEX NAME)



AB A review of synthetic methods to prepare thiazoles as well as reactive modifications of thiazole moieties.
REFERENCE COUNT: 1224 THERE ARE 1224 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L8 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:275966 CAPLUS
DOCUMENT NUMBER: 136:294739
TITLE: Preparation of pyridinyl-substituted benzamides as Apo B secretion inhibitors
INVENTOR(S): Takasugi, Hisashi; Terasawa, Takeshi; Inoue, Yoshikazu; Nakamura, Hideko; Nagayoshi, Akira; Ohtake, Hiroaki; Furukawa, Yoshiro; Mikami, Masafumi; Hinoue, Kazumasa; Ohtsubo, Makoto
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Daiso Co., Ltd.
SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028835	A1	20020411	WO 2001-JP8581	20010928
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2425097	AA	20020411	CA 2001-2425097	20010928

10/764,529


AU 2001092315	A5	20020415	AU 2001-92315	20010928
EP 1326835	A1	20030716	EP 2001-972612	20010928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001014657	A	20030930	BR 2001-14657	20010928
JP 2004510763	T2	20040408	JP 2002-532421	20010928
NZ 525591	A	20040430	NZ 2001-525591	20010928
NO 2003001540	A	20030605	NO 2003-1540	20030404
ZA 2003003371	A	20040730	ZA 2003-3371	20030430
US 2004058903	A1	20040325	US 2003-381737	20030903
PRIORITY APPLN. INFO.:				
			AU 2000-583	A 20001005
			AU 2001-6666	A 20010727
			WO 2001-JP8581	W 20010928

OTHER SOURCE(S): MARPAT 136:294739

IT **408367-83-9P**, N-[4-[2-[2-(Acetylamino)-1,3-thiazol-4-yl]ethyl]phenyl]-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide
408367-85-1P, N-[4-[2-(2-Acetylamino-1,3-thiazol-4-yl)vinyl]phenyl]-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Apo B inhibitor; preparation of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related conditions)
RN 408367-83-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethyl]phenyl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 408367-85-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[4-[2-[2-(acetylamino)-4-thiazolyl]ethenyl]phenyl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




10/764,529



IT 183365-29-9, N-[4-[2-(4-Aminophenyl)ethyl]-1,3-thiazol-2-yl]acetamide 408367-86-2, N-[4-[2-(4-Aminophenyl)vinyl]-1,3-thiazol-2-yl]acetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related conditions)
RN 183365-29-9 CAPLUS
CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 408367-86-2 CAPLUS
CN Acetamide, N-[4-[2-(4-aminophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [wherein R1 and R2 = independently alkyl, alkenyl, acyl, amino, (cyclo)alkoxy, aryl(oxy), sulfoxy, mercapto, sulfo, H, halo, NO₂, CN, or OH; or R1R2 = a ring; Q1 = N or CH; L = (un)substituted unsatd. 3 to 10-membered heterocyclic group; X = (un)substituted monocyclic (hetero)arylene; Y = (A1)_m(A2)_n(A4)_k; Z = direct bond, CH₂, NH, or O; R = H or alkyl; A1 = (un)substituted alkylene or alkenylene; A2 = NR₃, CONR₃, NHCONH, CO₂, O, O(CH₂)₂NR₃, S, SO, or SO₂; A4 = alkylene, alkenylene, or alkynylene; R₃ = H or suitable substituent; k, m, and n = independently 0 or 1; or a salt thereof] were prepared as apolipoprotein B (Apo B) secretion inhibitors. For example, to a suspension of N-(4-aminophenyl)-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide, 2-pyridinylacetic acid•HCl, and HOBT•H₂O in CH₂Cl₂ was added to WSC•HCl, followed by TEA at 5°C. The mixture was stirred at room temperature for 24 h and worked up to give II. The latter inhibited Apo B secretion by 100% at 10⁻⁶ M in HepG2 cells and lowered cholesterol by 83% and triglyceride by 35% after 2 h at a dose of 32 mg/kg in ddY-mice. I are useful for the prophylaxis and treatment of diseases or conditions resulting from elevated circulating levels of Apo B, such as hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus, obesity, coronary heart diseases, myocardial infarction, stroke, restenosis, and Syndrome X.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:51438 CAPLUS

DOCUMENT NUMBER: 136:118447

TITLE: Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors

10/764,529

INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Gillard, James;
Kukolj, George; Austel, Volkhard
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004425	A2	20020117	WO 2001-CA989	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002065418	A1	20020530	US 2001-898297	20010703
US 6448281	B2	20020910		
CA 2412718	AA	20020117	CA 2001-2412718	20010704
EP 1301487	A2	20030416	EP 2001-951274	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502761	T2	20040129	JP 2002-509292	20010704
US 6479508	B1	20021112	US 2001-995099	20011127
CA 2439176	AA	20020912	CA 2002-2439176	20020306
WO 2002070739	A2	20020912	WO 2002-CA323	20020306
WO 2002070739	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1370682	A2	20031217	EP 2002-712681	20020306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520839	T2	20040715	JP 2002-570761	20020306
NZ 528644	A	20050527	NZ 2002-528644	20020306
US 2003232816	A1	20031218	US 2002-238282	20020910
US 6794404	B2	20040921		
US 2004110126	A1	20040610	US 2004-471164	20040205
US 2004224955	A1	20041111	US 2004-851710	20040521
PRIORITY APPLN. INFO.:			US 2000-216084P	P 20000706
			US 2001-274374P	P 20010308
			US 2001-281343P	P 20010405
			US 2001-898297	A3 20010703
			WO 2001-CA989	W 20010704
			US 2001-995099	A3 20011127
			WO 2002-CA323	W 20020306

10/764,529

US 2002-238282

A1 20020910

OTHER SOURCE(S): MARPAT 136:118447

IT 390812-57-4P 390813-39-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

RN 390812-57-4 CAPLUS

CN Acetic acid, [4-[(2S)-3-[2-(acetylamino)-4-thiazolyl]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]propyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 390813-39-5 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-1-[2-(acetylamino)-4-thiazolyl]-2-(4-hydroxyphenyl)ethyl]-1-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. [I; X = CH, N; Y = O, S; Z = OH, NH₂, NMeR₃, NHR₃, OR₃, 5-6 membered (substituted) heterocyclyl; A = N, COR₇, CR₅; R₅ = H, halo, alkyl; R₇ = H, alkyl; X and A are not both N; R₆ = H, halo, alkyl, OR₇; R₇ = H, alkyl; R₁ = (substituted) hetero(bi)cyclyl, Ph, phenylalkyl, alkenyl, phenylalkenyl, cycloalkyl, alkyl, CF₃; R₂ = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, adamantyl, Ph, pyridyl; R₃ = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, alkenyl, cycloalkylalkenyl, arylalkenyl, dialkylamino, heterocyclyl, etc.; n = 0, 1], were prepared Thus, Me 3-amino-4-cyclohexylaminobenzoate (preparation given), 2-pyridinecarboxaldehyde, and Oxone were stirred in DMF to give 80% Et 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylate, which was saponified with aqueous NaOH in MeOH to give 91% 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylic acid. The latter inhibited hepatitis C virus RNA dependent polymerase (NS5B) with IC₅₀ = 1-5 μM.

L8 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:229500 CAPLUS

DOCUMENT NUMBER: 129:4607

TITLE: Aromatic ring opening of fused thiophenes via organolithium addition to sulfur

AUTHOR(S): Hill, B.; De Vleeschauwer, M.; Houde, K.; Belley, M.

CORPORATE SOURCE: Department Medicinal Chemistry, Merck Frosst Center Therapeutic Research, Kirkland, QC, H9H 3L1, Can.

SOURCE: Synlett (1998), (4), 407-410

CODEN: SYNLES; ISSN: 0936-5214

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:4607

IT 207229-66-1P 207229-72-9P


RL: SPN (Synthetic preparation); PREP (Preparation)

(ring opening of fused thiophenes via organolithium addition to sulfur)

RN 207229-66-1 CAPLUS

CN Acetamide, N-[5-(butylthio)-4-[(1E)-2-chloro-3-hydroxy-3-phenyl-1-propenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



10/764,529

RN 207229-72-9 CAPLUS

CN Acetamide, N-[5-(butylthio)-4-(3-hydroxy-3-phenyl-1-propynyl)-2-thiazolyl]-(9CI) (CA INDEX NAME)



AB Fused thiophenes substituted by at least 1 Cl react with organolithium reagents at -78° by addition to the S atom. The anion generated after ring opening adds to electrophiles or gives elimination products if there is a leaving group in position 3 of the thiophene. The reaction is not general and is highly dependent on the substitution pattern of the thiophene and the nature of the organolithium. Side reactions such as proton abstraction and Li-Cl exchange compete with the ring cleavage. Thiophenes that are not fused to another aromatic ring do not give rise to this reaction, the only known exception being 3,4-dichloro-2,5-dimethoxythiophene at room temperature

L8 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:694359 CAPLUS

DOCUMENT NUMBER: 125:328705

TITLE: Preparation of 2-anilino-2-thiazolines and analogs as nitric oxide synthase inhibitors

INVENTOR(S): Katsura, Yousuke; Nishino, Shigetaka; Tomishi, Tetsuo

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9630350	A1	19961003	WO 1996-JP776	19960326
W: AU, CA, CN, RU, TJ, TM	HU, JP, KR, MX, NO, NZ, US, AM, AZ, BY, KG, KZ, MD,			
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9650155	A1	19961016	AU 1996-50155	19960326
JP 11503121	T2	19990323	JP 1996-529162	19960326
PRIORITY APPLN. INFO.:			GB 1995-6188	A 19950327
			WO 1996-JP776	W 19960326

OTHER SOURCE(S): MARPAT 125:328705

IT 183365-33-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of 2-anilino-2-thiazolines and analogs as nitric oxide synthase inhibitors)

RN 183365-33-5 CAPLUS

CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-

10/764,529

thiazolyl]- (9CI) (CA INDEX NAME)




IT 183365-16-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-anilino-2-thiazolines and analogs as nitric oxide synthase inhibitors)

RN 183365-16-4 CAPLUS

CN Acetamide, N-[4-[3-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]propyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




IT 183365-27-7P 183365-28-8P 183365-29-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-anilino-2-thiazolines and analogs as nitric oxide synthase inhibitors)

RN 183365-27-7 CAPLUS


CN Acetamide, N-[4-[3-(4-nitrophenyl)propyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 183365-28-8 CAPLUS


CN Acetamide, N-[4-[(1E)-2-(4-nitrophenyl)ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/764,529

RN 183365-29-9 CAPLUS
CN Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R = Z2(CH2)nZ1(CH2)mR1; R1 = heterocyclyl; R2,R3 = H; R2R3 = O; Z = CH2, O, S, (alkyl)imino; Z1 = bond, CH2, O, S; Z2 = phenylene; m,n = 0 or 1] were prepared Thus, title compound II gave 95% inhibition of nitric oxide synthase at 10-5g/mL in vitro.

L8 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:70022 CAPLUS

DOCUMENT NUMBER: 118:70022

TITLE: photographic couplers and silver halide color photographic materials

INVENTOR(S): Takeuchi, Kihoshi; Sato, Kozo

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04204532	A2	19920724	JP 1990-330778	19901130
JP 2592354	B2	19970319		

PRIORITY APPLN. INFO.: JP 1990-330778 19901130


IT 93044-41-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and reaction of, in preparation of photog. coupler)

RN 93044-41-8 CAPLUS

CN Acetamide, N-[5-nitro-4-(2-phenylethenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



GI



AB Claimed are photog. couplers represented by general structure I. For I, R1, R2 = substituent; X = H, or group to be released upon coupling reaction with an oxidized aromatic primary amine developing agent. Also claimed are silver halide color photog. materials containing the couplers. The photog. materials give excellent color reproduction

L8 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:167461 CAPLUS

DOCUMENT NUMBER: 108:167461

TITLE: Preparation of aminoazoles as antiarthritics

INVENTOR(S): Ozato, Yukinori; Tamura, Nobuhiko; Masumori, Hiroaki; Yamamoto, Michihiro; Kojima, Atsuyuki; Nishikaku, Fumio; Kimura, Yoshihiko

PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 248399	A1	19871209	EP 1987-107959	19870602
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
US 4914112	A	19900403	US 1987-55079	19870528
JP 63152368	A2	19880624	JP 1987-139305	19870602
JP 04080035	B4	19921217		
US 5066666	A	19911119	US 1990-470731	19900126
US 5180731	A	19930119	US 1991-732169	19910718
JP 05247014	A2	19930924	JP 1991-208501	19910724
PRIORITY APPLN. INFO.:			JP 1986-128910	A 19860603
			JP 1986-164508	A 19860711
			US 1987-55079	A3 19870528
			US 1990-470731	A3 19900126

IT 113757-88-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiarthritic)

RN 113757-88-3 CAPLUS



CN Acetamide, N-[4-[1-(2-fluoro[1,1'-biphenyl]-4-yl)ethyl]-2-thiazolyl]-

10/764,529

(9CI) (CA INDEX NAME)



GI



AB ACHR3BNR1R2 [I; A = R4ZZ1, benzo-fused heterocyclic moiety Q, Q1; B = divalent azole; R1, R3 = H, alkyl; R2 = H, alkyl, aralkyl, R9Z2; R4 = (halo)phenyl, (halo)thienyl; R5 = alkoxy, (halo)phenyl; R6 = alkoxy; R7 = alkyl; R8 = (halo)benzoyl; R9 = H, aryl, R10R11N, R12O, (un)substituted alkyl; R10 = H, alkyl; R11 = H, alkyl, alkenyl, cycloalkyl, aralkyl, aroyl; R1R2N, R10R11N = 5-, 6-, or 7-membered, saturated heterocyclyl; R12 = (polyhalo)alkyl; X = CH2, N; Y = CH:CH, O; Z = CO, HOCH, NH, R13ON:C, bond, 1,3-dioxolan-2-ylidene; R13 = H, alkyl; Z1 = phenylene, thienylene; Z2 = CO, COCO, CS, SO2] and their acid salts were prepared for treating autoimmune diseases. 3,4-FPhC6H3CHR13Me (II, R13 = CO2H) was converted to its acid chloride and treated with (Me3SiO)2C:CHOSiMe3 to give II (R13 = COCH2OH). The latter was stirred with Ph3P in CCl4 to give II (R13 = COCH2Cl) which was heated with MeNHCSNH2 in H2O to give (methylamino)thiazole III. In the adjuvant arthritis test in rats III had a min. ED of 25 mg/kg/day orally for 5 days.

L8 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1979:557394 CAPLUS

DOCUMENT NUMBER: 91:157394

TITLE: Derivatives of 1-bromo-3-(3-hydroxy-6-acetoxy-2,4,5-trimethylphenyl)-2-propanone

AUTHOR(S): Makovetskii, V. P.; Dzvinchuk, I. B.; Svishchuk, A. A.

CORPORATE SOURCE: Inst. Org. Khim., Kiev, USSR

SOURCE: Ukrainskii Khimicheskii Zhurnal (Russian Edition) (1979), 45(7), 637-41

CODEN: UKZHAU; ISSN: 0041-6045

DOCUMENT TYPE: Journal

LANGUAGE: Russian

OTHER SOURCE(S): CASREACT 91:157394


IT 71558-41-3P

10/764,529


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 71558-41-3 CAPLUS

CN Acetamide, N-[4-[[2,5-bis(acetyloxy)-3,4,6-trimethylphenyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



GI



AB Brominating 5,2-RO(AcO)C6Me3CH2COME (R = H, Me) gave 66.9-70.1% 5,2-RO(AcO)C6Me3CH2COCH2Br (I). I (R = H) was acetylated to 94.0% I (R = Ac) (II), and was treated with R1CO2H (R1 = H, Me, Ph, 2-HOC6H4, 2-furyl) in Me2CO containing Et3N to give 90.5-3.5% 2,5-(AcO)2C6Me3CH2COCH2O2CR1. II also reacted with R2OH (R2 = Ph, 2-O2NC6H4) to give 88.5-92.5% 2,5-(AcO)2C6Me3CH(OR2)COME, or cyclized with thiourea to give 89.2% thiazole III.HBr (R = H), which gave 97.5% free base with NaOAc in DMF and then 98.2% III (R = Ac) with Ac2O.

L8 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1964:469168 CAPLUS

DOCUMENT NUMBER: 61:69168

ORIGINAL REFERENCE NO.: 61:12008b-d

TITLE: 5-Nitrothiazole derivatives

INVENTOR(S): Herrling, Siegfried; Mueckter, Heinrich

PATENT ASSIGNEE(S): Chemie Gruenenthal G.m.b.H.

SOURCE: 2 pp.; Addn. to Ger. 1159450

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1173097		19640702	DE	19621214
IT 92061-29-5,				
92164-96-0,				
thiazole, 2-acetamido-4-(p-cyanostyryl)-5-nitro-				
Benzoic acid, p-[2-(2-acetamido-5-nitro-4-				
thiazolyl)vinyl]- 98018-34-9,				
Benzenesulfonic acid,				
m-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]-				

10/764,529

(preparation of)


RN 92061-29-5 CAPLUS

CN Acetamide, N-[4-[2-(4-cyanophenyl)ethenyl]-5-nitro-2-thiazolyl]- (9CI)
(CA INDEX NAME)




RN 92164-96-0 CAPLUS

CN Benzoic acid, p-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]- (7CI) (CA
INDEX NAME)



RN 98018-34-9 CAPLUS

CN Benzenesulfonic acid, m-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]- (7CI)
(CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB 2-Acetamido-4-methyl-5-nitrothiazole (I) (4 g.) was refluxed with 25 ml. ProH, 3 g. pNCC6H4CHO, and 0.5 ml. piperidine 1 hr. to yield 56% 2-acetamido-4-(p-cyanostyryl)-5-nitrothiazole, m. 299-300°. Terephthalaldehydic acid (II) (1.8 g.) was dissolved with warming in 60 ml. ProH, 2 g. I and 1 ml. piperidine added, and the mixture refluxed 1 hr. to yield 39% 2-acetamido-4-(p-carboxystyryl)5-nitrothiazole (III), m. 300°. II (1.8 g.) was added to a solution of 1.5 g. diethanolamine in 20 ml. ProH and then treated with 2 g. I to give 63% III. I (2 g.) was refluxed with 4.5 g. the piperidine salt of benzaldehyde 3-sulfonic acid, 20 ml. ProH, and 0.5 ml. piperidine for 1 hr. to yield 27% 3-[2-(2-acetamido-5-nitrothiazol-4-ylvinyl)]benzenesulfonic acid, m. >300°.

L8 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1964:52762 CAPLUS

DOCUMENT NUMBER: 60:52762

ORIGINAL REFERENCE NO.: 60:9281h, 9282a-c

TITLE: 5-Nitrothiazoles

INVENTOR(S): Herrling, Siegfried; Mueckter, Heinrich


PATENT ASSIGNEE(S): Chemie Gruenenthal G.m.b.H.

SOURCE: 3 pp.


10/764,529

DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	DE 1159450		19631219	DE	19610527
IT	92044-76-3, Thiazole, 2-acetamido-4-(o-chlorostyryl)-5-nitro- 92044-77-4, Thiazole, 2-acetamido-4-(p-chlorostyryl)-5-nitro- 92164-97-1, Thiazole, 2-acetamido-4-[3,4-(methylenedioxy)styryl]-5-nitro- 92166-87-5, Thiazole, 2-acetamido-4-(o-methoxystyryl)-5-nitro- 92166-88-6, Thiazole, 2-acetamido-4-(p-methoxystyryl)-5-nitro- 92167-02-7, Phenol, 4-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]-2-methoxy- 92378-75-1, Thiazole, 2-acetamido-5-nitro-4-(p-nitrostyryl)- 92853-09-3, Thiazole, 2-acetamido-4-(3,4-dimethoxystyryl)-5-nitro- 93044-41-8, Thiazole, 2-acetamido-5-nitro-4-styryl- 93312-33-5, Thiazole, 2-acetamido-5-nitro-4-(3,4,5-trimethoxystyryl)- 93532-57-1, Thiazole, 2-acetamido-4-(m-chlorostyryl)-5-nitro- 93734-74-8, Acetanilide, 4'-[2-(2-acetamido-5-nitro-4-thiazolyl)-vinyl]- 97027-80-0, Thiazole, 2-acetamido-4-(2,4-dichlorostyryl)-5-nitro- 97027-81-1, Thiazole, 2-acetamido-4-(3,4-dichlorostyryl)-5-nitro- (preparation of)				
RN	92044-76-3 CAPLUS				
CN	Thiazole, 2-acetamido-4-(o-chlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)				



RN 92044-77-4 CAPLUS
CN Thiazole, 2-acetamido-4-(p-chlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)




RN 92164-97-1 CAPLUS
CN Thiazole, 2-acetamido-4-[3,4-(methylenedioxy)styryl]-5-nitro- (7CI) (CA INDEX NAME)



RN 92166-87-5 CAPLUS


10/764,529

CN Thiazole, 2-acetamido-4-(o-methoxystyryl)-5-nitro- (7CI) (CA INDEX NAME)




RN 92166-88-6 CAPLUS

CN Thiazole, 2-acetamido-4-(p-methoxystyryl)-5-nitro- (7CI) (CA INDEX NAME)




RN 92167-02-7 CAPLUS

CN Phenol, 4-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]-2-methoxy- (7CI) (CA INDEX NAME)




RN 92378-75-1 CAPLUS

CN Thiazole, 2-acetamido-5-nitro-4-(p-nitrostyryl)- (7CI) (CA INDEX NAME)



RN 92853-09-3 CAPLUS


CN Thiazole, 2-acetamido-4-(3,4-dimethoxystyryl)-5-nitro- (7CI) (CA INDEX NAME)



RN 93044-41-8 CAPLUS


10/764,529

CN Acetamide, N-[5-nitro-4-(2-phenylethenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 93312-33-5 CAPLUS

CN Thiazole, 2-acetamido-5-nitro-4-(3,4,5-trimethoxystyryl)- (7CI) (CA INDEX NAME)




RN 93532-57-1 CAPLUS

CN Thiazole, 2-acetamido-4-(m-chlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)




RN 93734-74-8 CAPLUS

CN Acetanilide, 4'-[2-(2-acetamido-5-nitro-4-thiazolyl)vinyl]- (7CI) (CA INDEX NAME)




RN 97027-80-0 CAPLUS

CN Thiazole, 2-acetamido-4-(2,4-dichlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)



RN 97027-81-1 CAPLUS

CN Thiazole, 2-acetamido-4-(3,4-dichlorostyryl)-5-nitro- (7CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB Title compds. (I) were prepared by condensation of RCHO with the corresponding 4-methyl-5-nitrothiazole in HCONMe₂, PrOH, or diethylene glycol di-Me ether, with piperidine or its acetate as catalyst. The following I (R₁ = NHAc) were prepared (R, m.p., and % yield given): Ph, 256-7°, 70; o-ClC₆H₄, 249-50°, 58; p-ClC₆H₄, >265°, 49; 3,4-dichlorophenyl, >250°, 45; 2,4-dichlorophenyl, >250°, 52; p-MeOC₆H₄, >270°, 67; o-MeOC₆H₄, 213-14°, 67; 3,4-dimethoxyphenyl, 217-19°, 62; 3-methoxy-4 hydroxyphenyl, 228-30°, 54; 3,4-methylenedioxyphenyl, >260°, 51; p-O₂NC₆H₄, >250°, 48; p-AcNHC₆H₄, >260°, 59; 2-furyl, 262-3°, 63; 2-thienyl, >250°, 65; 2-quinolyl, 267°, 69; 2-pyridyl, 255°, 86.5°; 3-pyridyl, >260°, 78; m-ClC₆H₄, 245-7°, 56; 4-phenylthiazolyl, 245-7°, 43; 3,4,5-trimethoxyphenyl, 268-9°, 79.5. The following I (R₁ = Me) were prepared: Ph, 106°, 77; 3,4-dimethoxyphenyl, 158-9°, 51.5; m-MeOC₆H₄, 125-7°, 37; 3-ethoxy-4-methoxyphenyl, 122-4°, 41.6; 3,4,5-trimethoxyphenyl, 119-21°, 45; o-ClC₆H₄, 127-9°, 39; 2-furyl, 124-7°, 35. Also were prepared the following I (R, R₁, m.p., and % yield given): MeS, Ph, 102-3°, 61; MeS, 3-pyridyl, 161-3°, 58; H, Ph, 196-8°, 37. I (R = 4-pyridyl, R₁ = NHAc) at 1 p.p.m. was active against Staphylococcus. I (R = 3- or 4-pyridyl, R₂ = NHAc) were active in 20-50% of mice infected with meningitis. I (R = 2-quinolyl, R₁ = NHAc) at 1:200,000 and I (R = 3,4-dimethoxyphenyl, R₁ = Me) at 1:1,000,000 were active against Trichomonas. The last compound at 1:250,000 and I (R = 3,4-dimethoxyphenyl, R₂ = NHAc) at 1:100,000 were amebicides.

L8 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1963:85538 CAPLUS

DOCUMENT NUMBER: 58:85538

ORIGINAL REFERENCE NO.: 58:1448b-e

TITLE: 2-Aminothiazole derivatives. II

AUTHOR(S): Mahajanshettti, C. S.; Acharya, S. P.; Nargund, K. S.

CORPORATE SOURCE: Karnatak Univ., Dharwar, India


SOURCE: J. Indian Chem. Soc. (1962), 39, 427-31

DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable

IT 91267-83-3, Ketone, 2-acetamido-5-bromo-4-thiazolyl
 2,4-dichlorophenyl 91267-84-4, Ketone, 2-acetamido-5-bromo-4-
 thiazolyl 2,5-dichlorophenyl 91267-85-5, Ketone,
 2-acetamido-5-bromo-4-thiazolyl 3,4-dichlorophenyl 91354-10-8,
 Ketone, 2-acetamido-5-bromo-4-thiazolyl p-chlorophenyl 91392-18-6
 , Thiazole, 2-acetamido-4-benzyl- 91394-59-1, Thiazole,
 2-acetamido-5-bromo-4-(p-chlorobenzyl)- 91394-82-0, Thiazole,
 2-acetamido-5-bromo-4-(p-nitrobenzyl)- 91395-06-1, Ketone,
 2-acetamido-4-thiazolyl 2,4-dichlorophenyl 91395-07-2, Ketone,
 2-acetamido-4-thiazolyl 2,5-dichlorophenyl 91395-08-3, Ketone,
 2-acetamido-4-thiazolyl 3,4-dichlorophenyl 91397-47-6, Thiazole,
 2-acetamido-4-(p-nitrobenzyl)- 91397-80-7, Thiazole,
 2-acetamido-4-benzyl-5-(chloromercuri)- 91492-91-0, Thiazole,
 2-acetamido-5-(chloromercuri)-4-(2,5-dichlorobenzyl)- 91498-42-9
 , Ketone, 2-acetamido-4-thiazolyl p-chlorophenyl 91570-76-2,
 Thiazole, 2-acetamido-4-benzyl-5-bromo- 91762-15-1, Thiazole,
 2-acetamido-5-(chloromercuri)-4-(p-methylbenzyl)- 91762-16-2,
 Thiazole, 2-acetamido-5-(chloromercuri)-4-p-methoxybenzyl)-
 91762-42-4, Thiazole, 2-acetamido-4-(2-chloro-4-methoxybenzyl)-
 91806-50-7, Thiazole, 2-acetamido-4-(p-methylbenzyl)-
 91806-90-5, Thiazole, 2-acetamido-4-(p-methoxybenzyl)-
 91955-36-1, Ketone, 2-acetamido-4-thiazolyl p-tolyl
 91955-68-9, Ketone, 2-acetamido-4-thiazolyl p-methoxyphenyl
 91961-80-7, Thiazole, 2-acetamido-4-(p-chlorobenzyl)-5-
 (chloromercuri)- 91961-87-4, Thiazole, 2-acetamido-4-(2,4-
 dichlorobenzyl)- 91961-88-5, Thiazole, 2-acetamido-4-(2,5-
 dichlorobenzyl)- 91961-89-6, Thiazole, 2-acetamido-4-(3,4-
 dichlorobenzyl)- 92022-29-2, Ketone, 2-acetamido-5-bromo-4-
 thiazolyl p-tolyl 92025-09-7, Thiazole, 2-acetamido-5-bromo-4-
 (2,4-dichlorobenzyl)- 92025-10-0, Thiazole, 2-acetamido-5-bromo-
 4-(2,5-dichlorobenzyl)- 92025-11-1, Thiazole,
 2-acetamido-5-bromo-4-(3,4-dichlorobenzyl)- 92025-16-6, Ketone,
 2-acetamido-5-bromo-4-thiazolyl phenyl 92696-30-5, Thiazole,
 2-acetamido-5-(chloromercuri)-4-(2,4-dichlorobenzyl)- 92696-31-6
 , Thiazole, 2-acetamido-5-(chloromercuri)-4-(3,4-dichlorobenzyl)-
 92696-79-2, Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl
 phenyl 92849-20-2, Thiazole, 2-acetamido-5-bromo-4-(p-
 methylbenzyl)- 92849-29-1, Thiazole, 2-acetamido-5-bromo-4-(p-
 methoxybenzyl)- 93308-00-0, Ketone, 2-acetamido-5-bromo-4-
 thiazolyl p-methoxyphenyl 93308-06-6, Ketone,
 2-acetamido-5-(chloromercuri)-4-thiazolyl p-tolyl 93308-07-7,
 Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-methoxyphenyl
 93352-50-2, Ketone, 2-acetamido-4-thiazolyl phenyl
 97026-22-7, Thiazole, 2-acetamido-5-bromo-4-(2-chloro-4-
 methoxybenzyl)- 107084-04-8, Thiazole, 2-acetamido-5-
 (chloromercuri)-4-(2-chloro-4-methoxybenzyl)-
 (preparation of)


RN 91267-83-3 CAPLUS
 CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 2,4-dichlorophenyl (7CI) (CA
 INDEX NAME)

10/764,529




RN 91267-84-4 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 2,5-dichlorophenyl (7CI) (CA INDEX NAME)




RN 91267-85-5 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 3,4-dichlorophenyl (7CI) (CA INDEX NAME)




RN 91354-10-8 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-chlorophenyl (7CI) (CA INDEX NAME)



RN 91392-18-6 CAPLUS


CN Thiazole, 2-acetamido-4-benzyl- (7CI) (CA INDEX NAME)



10/764,529


RN 91394-59-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-chlorobenzyl)- (7CI) (CA INDEX NAME)




RN 91394-82-0 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-nitrobenzyl)- (7CI) (CA INDEX NAME)




RN 91395-06-1 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl 2,4-dichlorophenyl (7CI) (CA INDEX NAME)



RN 91395-07-2 CAPLUS


CN Ketone, 2-acetamido-4-thiazolyl 2,5-dichlorophenyl (7CI) (CA INDEX NAME)



RN 91395-08-3 CAPLUS


CN Ketone, 2-acetamido-4-thiazolyl 3,4-dichlorophenyl (7CI) (CA INDEX NAME)

10/764,529




RN 91397-47-6 CAPLUS

CN Thiazole, 2-acetamido-4-(p-nitrobenzyl)- (7CI) (CA INDEX NAME)




RN 91397-80-7 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-(chloromercuri)- (7CI) (CA INDEX NAME)




RN 91492-91-0 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)



RN 91498-42-9 CAPLUS


CN Ketone, 2-acetamido-4-thiazolyl p-chlorophenyl (7CI) (CA INDEX NAME)



10/764,529


RN 91570-76-2 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-bromo- (7CI) (CA INDEX NAME)




RN 91762-15-1 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)




RN 91762-16-2 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)




RN 91762-42-4 CAPLUS

CN Thiazole, 2-acetamido-4-(2-chloro-4-methoxybenzyl)- (7CI) (CA INDEX NAME)



RN 91806-50-7 CAPLUS


CN Thiazole, 2-acetamido-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)



RN 91806-90-5 CAPLUS


10/764,529

CN Thiazole, 2-acetamido-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)




RN 91955-36-1 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)




RN 91955-68-9 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)




RN 91961-80-7 CAPLUS

CN Thiazole, 2-acetamido-4-(p-chlorobenzyl)-5-(chloromercuri)- (7CI) (CA INDEX NAME)



RN 91961-87-4 CAPLUS


CN Thiazole, 2-acetamido-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)




RN 91961-88-5 CAPLUS

CN Thiazole, 2-acetamido-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)


10/764,529




RN 91961-89-6 CAPLUS
CN Thiazole, 2-acetamido-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)



RN 92022-29-2 CAPLUS
CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)




RN 92025-09-7 CAPLUS
CN Thiazole, 2-acetamido-5-bromo-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)




RN 92025-10-0 CAPLUS
CN Thiazole, 2-acetamido-5-bromo-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)

10/764,529




RN 92025-11-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)




RN 92025-16-6 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl phenyl (7CI) (CA INDEX NAME)



RN 92696-30-5 CAPLUS


CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)



RN 92696-31-6 CAPLUS


CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

10/764,529




RN 92696-79-2 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl phenyl (7CI) (CA INDEX NAME)




RN 92849-20-2 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)




RN 92849-29-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)



RN 93308-00-0 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)




RN 93308-06-6 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)


10/764,529

NAME)




RN 93308-07-7 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-methoxyphenyl (7CI)
(CA INDEX NAME)




RN 93352-50-2 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl phenyl (7CI) (CA INDEX NAME)




RN 97026-22-7 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(2-chloro-4-methoxybenzyl)- (7CI) (CA
INDEX NAME)



RN 107084-04-8 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2-chloro-4-methoxybenzyl)-
(7CI) (CA INDEX NAME)



AB Ph 2-amino-5-thiazolyl sulfides (I) and sulfones (II), having various substituents in the Ph ring, were prepared for evaluation of their antibacterial properties. Various required thiophenols were prepared by the Leuckart reaction from the corresponding anilines, whereas 3,4- and 3,6-Br(MeO)C₆H₃SH were prepared by reduction of the corresponding sulfonyl chlorides. 2-Acetamido-5-bromothiazole (III) was prepared by the method of Backer and Buisman (CA 40, 24463). III (0.02 mol), 0.02 mol K salt of a thiophenol, and 15-20 mL MeCH(OH)CH₂OH heated 4 h. at 130-40°, the mixture cooled, poured into H₂O, the precipitate macerated with 10% aqueous NaOH (some deacetylation occurred), filtered off, washed with H₂O, dried, heated 15 min. with 10 mL Ac₂O, and worked up in the usual way gave the Ac derivative (IV) of I. To 0.5 g. I in AcOH was added 2 mL 30% H₂O₂, kept 60 h. with intermittent addition of 0.5 mL 30% H₂O at intervals of 20 h., the precipitate filtered off (if no solid separated the solution was diluted with H₂O), and crystallized from AcOH gave the Ac derivative (V) of corresponding II. The following IV and V were prepared [substituent(s) in Ph ring, % yield IV, m.p., m.p. corresponding V given]: none 80, 226-7° 273-4°; 2,4-Br, Me, 78, 202-3°, 261-2°; 2,4-Me, Br, 80, 204-5°, 290-1°; 3,4-Cl, Br, 75, 195-6°, 262-3°; 3,4-Br(MeO), 78, 248-9°, 266-7°; 3,6-Br(MeO), 70, 210-11°, 237-8°; 2,5,4-Cl₂(EtO), 66, 212-13°, 280° (decomposition); 3,4-Cl(PrO), 72, 145-6°, 216-17°; 2,4-Cl(BuO), 70, 164-5, 214-15°; 2,3-Cl₂, 80, 229-30°, 265-6°; 2,4-Cl₂, 70, 209-10°, 292-3°; 2,5-Cl₂, 76, 222-4°, 245-6°. The IV or V (0.5 g.) in 20-5 mL EtOH-containing 2 mL concentrated HCl refluxed 2 h., concentrated in vacuo, and the residue treated with dilute aqueous NH₃ gave corresponding I and II, resp. The following I and II were prepared (substituents in Ph ring, m.p. I, m.p. I.HCl, m.p. corresponding II given): none, 135-6°, 183-4°, 227-8°; 2,4-Br, Me, 169-70°, 191-2°, 210-11°; 2,4-Me, Br, 254-5°, 205-6°, 182-3°; 3,4-Cl, Br, 125-6°, 186-7°, 220-1°; 3,4-Br(MeO), 164-5°, 195-6°, 203-4°; 3,5-Br(MeO), 142-3°, 108-9°, 218-19°; 2,5,4-Cl₂(EtO), 152-3°, 197-8°, 249-50°; 3,4-Cl(PrO), 110-11°, 89-90°, 191-2°; 2,4-Cl(BuO), 86-7°, 82-3°, 151-2°; 2,3-Cl₂, 175-6°, 211-12°, 219-20°; 2,4-Cl₂, 166-7°, 198-9°, 186-7°; 2,5-Cl₂, 82-3°, 181-2°, 227-8°. Some of the compds. were found to be bacteriostatic in vitro against E. coli and S. aureus.


L8 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1963:8817 CAPLUS
 DOCUMENT NUMBER: 58:8817
 ORIGINAL REFERENCE NO.: 58:1447b-h,1448a-b
 TITLE: 2-Aminothiazole derivatives I
 AUTHOR(S): Mahajanshetti, C. S.; Nargund, K. S.
 CORPORATE SOURCE: Karnatak Univ., Dharwar, India

SOURCE: J. Indian Chem. Soc. (1962), 39, 420-6
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable

IT 91267-83-3, Ketone, 2-acetamido-5-bromo-4-thiazolyl
 2,4-dichlorophenyl 91267-84-4, Ketone, 2-acetamido-5-bromo-4-
 thiazolyl 2,5-dichlorophenyl 91267-85-5, Ketone,
 2-acetamido-5-bromo-4-thiazolyl 3,4-dichlorophenyl 91354-10-8,
 Ketone, 2-acetamido-5-bromo-4-thiazolyl p-chlorophenyl 91392-18-6
 , Thiazole, 2-acetamido-4-benzyl- 91394-59-1, Thiazole,
 2-acetamido-5-bromo-4-(p-chlorobenzyl)- 91394-82-0, Thiazole,
 2-acetamido-5-bromo-4-(p-nitrobenzyl)- 91395-06-1, Ketone,
 2-acetamido-4-thiazolyl 2,4-dichlorophenyl 91395-07-2, Ketone,
 2-acetamido-4-thiazolyl 2,5-dichlorophenyl 91395-08-3, Ketone,
 2-acetamido-4-thiazolyl 3,4-dichlorophenyl 91397-47-6, Thiazole,
 2-acetamido-4-(p-nitrobenzyl)- 91397-80-7, Thiazole,
 2-acetamido-4-benzyl-5-(chloromercuri)- 91492-91-0, Thiazole,
 2-acetamido-5-(chloromercuri)-4-(2,5-dichlorobenzyl)- 91498-42-9
 , Ketone, 2-acetamido-4-thiazolyl p-chlorophenyl 91570-76-2,
 Thiazole, 2-acetamido-4-benzyl-5-bromo- 91762-15-1, Thiazole,
 2-acetamido-5-(chloromercuri)-4-(p-methylbenzyl)- 91762-16-2,
 Thiazole, 2-acetamido-5-(chloromercuri)-4-p-methoxybenzyl)-
 91762-42-4, Thiazole, 2-acetamido-4-(2-chloro-4-methoxybenzyl)-
 91806-50-7, Thiazole, 2-acetamido-4-(p-methylbenzyl)-
 91806-90-5, Thiazole, 2-acetamido-4-(p-methoxybenzyl)-
 91955-36-1, Ketone, 2-acetamido-4-thiazolyl p-tolyl
 91955-68-9, Ketone, 2-acetamido-4-thiazolyl p-methoxyphenyl
 91961-80-7, Thiazole, 2-acetamido-4-(p-chlorobenzyl)-5-
 (chloromercuri)- 91961-87-4, Thiazole, 2-acetamido-4-(2,4-
 dichlorobenzyl)- 91961-88-5, Thiazole, 2-acetamido-4-(2,5-
 dichlorobenzyl)- 91961-89-6, Thiazole, 2-acetamido-4-(3,4-
 dichlorobenzyl)- 92022-29-2, Ketone, 2-acetamido-5-bromo-4-
 thiazolyl p-tolyl 92025-09-7, Thiazole, 2-acetamido-5-bromo-4-
 (2,4-dichlorobenzyl)- 92025-10-0, Thiazole, 2-acetamido-5-bromo-
 4-(2,5-dichlorobenzyl)- 92025-11-1, Thiazole,
 2-acetamido-5-bromo-4-(3,4-dichlorobenzyl)- 92025-16-6, Ketone,
 2-acetamido-5-bromo-4-thiazolyl phenyl 92696-30-5, Mercury,
 [2-acetamido-4-(2,4-dichlorobenzyl)-5-thiazolyl]chloro- 92696-31-6
 , Mercury, [2-acetamido-4-(3,4-dichlorobenzyl)-5-thiazolyl]chloro-
 92696-79-2, Mercury, (2-acetamido-4-benzoyl-5-thiazolyl)chloro-
 92849-20-2, Thiazole, 2-acetamido-5-bromo-4-(p-methylbenzyl)-
 92849-29-1, Thiazole, 2-acetamido-5-bromo-4-(p-methoxybenzyl)-
 93308-00-0, Ketone, 2-acetamido-5-bromo-4-thiazolyl
 p-methoxyphenyl 93308-06-6, Mercury, (2-acetamido-4-p-toluoyl-5-
 thiazolyl)chloro- 93308-07-7, Ketone, 2-acetamido-5-
 (chloromercuri)-4-thiazolyl p-methoxyphenyl 93352-50-2, Ketone,
 2-acetamido-4-thiazolyl phenyl 97026-22-7, Thiazole,
 2-acetamido-5-bromo-4-(2-chloro-4-methoxybenzyl)- 107084-04-8,
 Thiazole, 2-acetamido-5-(chloromercuri)-4-(2-chloro-4-methoxybenzyl)-
 (preparation of)


RN 91267-83-3 CAPLUS
 CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 2,4-dichlorophenyl (7CI) (CA
 INDEX NAME)

10/764,529




RN 91267-84-4 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 2,5-dichlorophenyl (7CI) (CA INDEX NAME)




RN 91267-85-5 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl 3,4-dichlorophenyl (7CI) (CA INDEX NAME)




RN 91354-10-8 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-chlorophenyl (7CI) (CA INDEX NAME)



RN 91392-18-6 CAPLUS


CN Thiazole, 2-acetamido-4-benzyl- (7CI) (CA INDEX NAME)



10/764,529


RN 91394-59-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-chlorobenzyl)- (7CI) (CA INDEX NAME)




RN 91394-82-0 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-nitrobenzyl)- (7CI) (CA INDEX NAME)




RN 91395-06-1 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl 2,4-dichlorophenyl (7CI) (CA INDEX NAME)



RN 91395-07-2 CAPLUS


CN Ketone, 2-acetamido-4-thiazolyl 2,5-dichlorophenyl (7CI) (CA INDEX NAME)



RN 91395-08-3 CAPLUS


CN Ketone, 2-acetamido-4-thiazolyl 3,4-dichlorophenyl (7CI) (CA INDEX NAME)

10/764,529




RN 91397-47-6 CAPLUS

CN Thiazole, 2-acetamido-4-(p-nitrobenzyl)- (7CI) (CA INDEX NAME)




RN 91397-80-7 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-(chloromercuri)- (7CI) (CA INDEX NAME)




RN 91492-91-0 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)



RN 91498-42-9 CAPLUS


CN Ketone, 2-acetamido-4-thiazolyl p-chlorophenyl (7CI) (CA INDEX NAME)



10/764,529


RN 91570-76-2 CAPLUS

CN Thiazole, 2-acetamido-4-benzyl-5-bromo- (7CI) (CA INDEX NAME)




RN 91762-15-1 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)




RN 91762-16-2 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)




RN 91762-42-4 CAPLUS

CN Thiazole, 2-acetamido-4-(2-chloro-4-methoxybenzyl)- (7CI) (CA INDEX NAME)




RN 91806-50-7 CAPLUS

CN Thiazole, 2-acetamido-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)




RN 91806-90-5 CAPLUS


CN Thiazole, 2-acetamido-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)




CN Ketone, 2-acetamido-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)




CN Ketone, 2-acetamido-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)



Thiazole, 2-acetamido-4-(p-chlorobenzyl)-5-(chloromercuri)- (7CI) (CA INDEX NAME)




CN Thiazole, 2-acetamido-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)




CN Thiazole, 2-acetamido-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)


10/764,529




RN 91961-89-6 CAPLUS
CN Thiazole, 2-acetamido-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)



RN 92022-29-2 CAPLUS
CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)




RN 92025-09-7 CAPLUS
CN Thiazole, 2-acetamido-5-bromo-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)




RN 92025-10-0 CAPLUS
CN Thiazole, 2-acetamido-5-bromo-4-(2,5-dichlorobenzyl)- (7CI) (CA INDEX NAME)


10/764,529




RN 92025-11-1 CAPLUS
CN Thiazole, 2-acetamido-5-bromo-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)



RN 92025-16-6 CAPLUS
CN Ketone, 2-acetamido-5-bromo-4-thiazolyl phenyl (7CI) (CA INDEX NAME)




RN 92696-30-5 CAPLUS
CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)




RN 92696-31-6 CAPLUS
CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(3,4-dichlorobenzyl)- (7CI) (CA INDEX NAME)

10/764,529




RN 92696-79-2 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl phenyl (7CI) (CA INDEX NAME)




RN 92849-20-2 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-methylbenzyl)- (7CI) (CA INDEX NAME)




RN 92849-29-1 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(p-methoxybenzyl)- (7CI) (CA INDEX NAME)



RN 93308-00-0 CAPLUS

CN Ketone, 2-acetamido-5-bromo-4-thiazolyl p-methoxyphenyl (7CI) (CA INDEX NAME)




RN 93308-06-6 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-tolyl (7CI) (CA INDEX NAME)


10/764,529

NAME)




RN 93308-07-7 CAPLUS

CN Ketone, 2-acetamido-5-(chloromercuri)-4-thiazolyl p-methoxyphenyl (7CI)
(CA INDEX NAME)




RN 93352-50-2 CAPLUS

CN Ketone, 2-acetamido-4-thiazolyl phenyl (7CI) (CA INDEX NAME)




RN 97026-22-7 CAPLUS

CN Thiazole, 2-acetamido-5-bromo-4-(2-chloro-4-methoxybenzyl)- (7CI) (CA
INDEX NAME)



RN 107084-04-8 CAPLUS

CN Thiazole, 2-acetamido-5-(chloromercuri)-4-(2-chloro-4-methoxybenzyl)-
(7CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB A series of 2-amino-4-benzyl- and 4-benzoylthiazoles along with their 2-acetamido-5-chloromercuri and 2-acetamido-5-bromo analogs were prepared for evaluation of their chemotherapeutic properties. Various propiophenones and acetophenones were prepared by the Friedel-Crafts reaction on substituted benzenes. α -Isonitrosopropiophenones were prepared according to Hartung and Crossley [Organic Syntheses, Collective

Volume

II, 363(1950)]. α -Isonitroso-2',4'-dichloropropiophenone and its 3',4'-dichloro and 2',5'-dichloro isomers were new compds. and m. 115-16° 158-69°, and 147-8°, resp. The appropriate α -isonitrosopropiophenone and 10-15% aqueous H₂SO₄ (1:10 proportion by weight) steam distilled until no more oil appeared in the distillate, the heavy oil or solid in the distillate separated, the aqueous layer saturated with

salt, extracted

with Et₂O, the combined oil or solid and extract washed with 2% aqueous NaHCO₃, dried, evaporated, and the residue distd, in vacuo or crystallized from a

suitable

solvent gave the following RCOAc (I) (R, % yield, m.p., b.p./ mm. given):

4-MeC₆H₄, 60, --, 117-20°/5; 4-MeOC₆H₄, 60, 46-7°, --;

4-ClC₆H₄, 50, --, 140-4°/20; 4-O₂NC₆H₄, 59, 91-2° --;

2,4-Cl₂C₆H₃, 40, --, 142-7°/10; 3,4-Cl₂C₆H₃, 40, 47-8°, --;

2,5-Cl₂C₆H₃, 38, --, 154-7°/12. I (R = Ph) (0.02 mole) in 50 ml.

boiling CS₂ treated dropwise with the calculated amount Br in CS₂ in sunlight, the solution refluxed 0.5 hr., evaporated, the residue dissolved in Et₂O, the solution washed with 2% aqueous Na₂S₂O₃, dried, treated with 0.02 mole powdered thiourea (exothermic reaction started soon), the mixture refluxed gently 30 min., the precipitate filtered off, washed with Et₂O, suspended in H₂O, and the mixture basified with dilute aqueous NH₃ gave 66% II (R = Ph, R' = R'' = H), m. 160-1°; HCl salt m. 98-9°; Ac derivative (III) m. 195-6°;

semicarbazone m. 220-1° (decomposition). To 0.5 g. III in hot EtOH was

added 0.7 g. HgCl₂ and 1.2 g. NaOAc in H₂O with shaking, the mixture refluxed 1 hr., cooled, the precipitate filtered off, washed with hot H₂O,

EtOH,

and Et₂O, air dried, dissolved in AcOH, and the solution diluted with H₂O to give II (R = Ph, R' = Ac, R'' = HgCl) (IV), m. 273-4°. To a saturated solution of NaBr in 15 ml. MeOH was added 0.5 g. IV followed by a few drops Br until the red color persisted, the mixture shaken, treated with Na₂SO₃ to remove excess Br, refluxed 30 min., filtered while hot, the filtrate concentrated, and diluted with a min. amount H₂O to give II (R = Ph, R' = Ac,

R'' =

Br), m. 199-200°. The following II were prepared similarly (R, R', R'', % yield, m.p., m.p. HCl salt, m.p. Ac derivative, m.p. semicarbazone, m.p. 2-acetamido-5-chloromercuri analog, m.p. 2-acetamido-5-bromo analog given): 4-MeC₆H₄, H, H, 70, 153-4°, 215-16°, 200-1°, 208° (decomposition), 285-6°, 168-9°; 4-MeOC₆H₄, H, H, 67, 155-6°, 222° (decomposition), 197-8°, 231° (decomposition), 284° (blackens), 177-8°; 4-ClC₆H₄, H, H, 67, 157-8°, 234-5°, 217-18°, 207° (decomposition), 288-9°, 177-8° 2,4-Cl₂C₆H₃, H, H, 47, 203-4°, 209-10°

179-80°, 198° (decomposition), 255° (blackens), 206-7°; 3,4-Cl₂C₆H₃, H, H, 50. 198-9°, 215-16°, 217-18°, 174-5°, 282-3°, 208-9°; 2,5-Cl₂C₆H₃, H, H, 47, 168-9°, 202-3°, 190-1°, 204° (decomposition), 255° (decomposition), 200-1°. To ice cold Et₂O-CH₂N₂ (prepared from 25 g. H₂NCONMeNO and 75 ml. 50% aqueous KOH) was added 0.05 mole PhCH₂COC₂Cl in ice cold Et₂O at below 5° with stirring, the whole stirred 5 hrs., treated with a stream of dry HCl until evolution of N ceased, kept 2 hrs., poured over crushed ice, the Et₂O layer separated, washed with H₂O and 5% aqueous NaHCO₃, dried, evaporated, and the residue distilled

in vacuo

(or crystallized in other cases) gave RCH₂COCH₂Cl (V) (R = Ph). The following V were prepared (R, % yield, m.p., b.p./mm. given): 4-MeC₆H₄, 80, --, 135-40°/7; 4-MOC₆H₄, 78, --, 161-3°/15; 4-ClC₆H₄, 75, --, 155-60°/6; 2,4-Cl₂C₆H₃, 80, 72-3°, --; 2,5-Cl₂C₆H₃, 78, 73-4°, --; 3,4-Cl₂C₆H₃, 75, --, 170-5°/10; 2,4-Cl(MeO)C₆H₃, 75, --, 172-6°/8. V (R = Ph) (0.02 mole), 0.02 mole powdered thiourea, and 20-5 m.l. EtOH refluxed 4 hrs., concentrated in vacuo, and the residue basified with aqueous NH₃ gave 70% VI (R = Ph), m. 92-3°; Ac derivative m. 190-1°; 2-acetamido-5-chloromercuri analog (prepared as above) m. 291° (decomposition); 2-acetamido-5-bromo analog (prepared as above) m. 164-5°. The following VI were prepared similarly (R, % yield, m.p., m.p. Ac derivative, m.p. 2-acetamido-5-chloromercuri analog, m.p. 2-acetamido-5-bromo analog given): 4-MeC₆H₄, 73, 109-10°, 1147-8°, 264-5°, 177-8°; 4-MeOC₆H₄, 75, 186-7°, 190-1°, 258-9°, 163-4°; 4-ClC₆H₄, 68, 141-2°, 166-7°, 271-2°, 182-3°; 2,4-Cl₂C₆H₃, 70, 97-8°, 184-5°, 286-7°, 200-1°; 2,5-Cl₂C₆H₃, 67, 104-5°, 189-90°, 285-6°, 181-2°; 3,4-Cl₂C₆H₃, 72, 119-20°, 155-6°, 280-1°, 235-6°; 2,4-Cl(MeO)C₆H₃, 70, 140-1°, 169-70°, 289-90°, 189-90°; 4-O₂NC₆H₄, 65, 172-3°, 188-9°, 269-70°, 185-6°. Some of the compds. were found to be bacteriostatic in vitro against Escherichia coli and Staphylococcus aureus.

L8 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1962:7698 CAPLUS

DOCUMENT NUMBER: 56:7698

ORIGINAL REFERENCE NO.: 56:1447f-i,1448a-i,1449a-i,1450a-i,1451a-i

TITLE: A new cinnoline synthesis. I. Cyclization of mesoxalyl chloride phenylhydrazones to give substituted 4-hydroxycinnoline-3-carboxylic acids

AUTHOR(S): Barber, H. J.; Washbourn, K.; Wragg, W. R.; Lunt, E.

CORPORATE SOURCE: May & Baker Ltd., Dagenham, UK

SOURCE: Journal of the Chemical Society, Abstracts (1961) 2828-843

CODEN: JCSAAZ; ISSN: 0590-9791

DOCUMENT TYPE: Journal


LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 56:7698

IT 91397-95-4, Thiazole, 2-acetamido-4-(p-chlorobenzyl)- (preparation of)

RN 91397-95-4 CAPLUS

CN Thiazole, 2-acetamido-4-(p-chlorobenzyl)- (7CI) (CA INDEX NAME)



AB A series of 4-hydroxycinnoline-3-carboxylic acids (I) was prepared from suitably substituted phenylhydrazones of $\text{CO}(\text{CO}_2\text{Et})_2$ (II). The I were converted by decarboxylation to the corresponding 4-hydroxycinnolines (III). Except for a single case, attempts to extend the scope of the synthesis to a wide variety of glyoxylic ester phenylhydrazones were unsuccessful. o- $\text{PhCH}_2\text{OC}_6\text{H}_4\text{NO}_2$ (199 g.) in 2 l. EtOH hydrogenated in the presence of 6 g. PtO_2 at $40^\circ/6$ atmospheric during 4.5 hrs. gave 162 g. o- $\text{PhCH}_2\text{OC}_6\text{H}_4\text{NH}_2$, b0.1 $150-6^\circ$, m. $37-9^\circ$. o- $\text{O}_2\text{NC}_6\text{H}_4\text{O}_3\text{SC}_6\text{H}_4\text{Me-p}$ (IV) (384 g.) in 4 l. EtOH hydrogenated 7.5 hrs. at 6 atmospheric and 70° over 8 g. PtO_2 gave 316 g. o- NH_2 analog of IV, buff plates, m. $97-8^\circ$. p- $\text{O}_2\text{NC}_6\text{H}_4\text{OCO}_2\text{Et}$ (444 g.) in 2.5 l. EtOH hydrogenated 40 min. at room temperature/20 atmospheric over 4.4 g. PtO_2 yielded 350 g. p- $\text{H}_2\text{NC}_6\text{H}_4\text{OCO}_2\text{Et}$, buff solid, m. $73-4^\circ$ (C_6H_6). Molten o- $\text{ClC}_6\text{H}_4\text{NH}_2$ (1.275 kg.) added to 2.5 l. concentrated HCl, the mixture cooled to 0° , mixed with 5 kg. ice, diazotized at $0-5^\circ$ with 705 g. NaNO_2 in 1.67 l. H_2O , filtered, added dropwise during 0.5 hr. with stirring to 1.6 l. $\text{CH}_2(\text{CO}_2\text{Et})_2$, 20 l. EtOH, 1.88 g. NaOAc , and 3 l. H_2O at 0° , stirred 5 hrs., and filtered gave 2.836 kg. (crude) o- $\text{ClC}_6\text{H}_4\text{NHN:C}(\text{CO}_2\text{Et})_2$, m. $76-7^\circ$ (EtOH). Similarly were prepared the following $\text{XC}_6\text{H}_4\text{NHN:C}(\text{CO}_2\text{Et})_2$ (X, crystal form, m.p., and % yield given): H (V), plates, $33-4^\circ$ (petr. ether) [b0.2 $145-50^\circ$], 95; o-Me, needles, $89-90^\circ$ (petr. ether), 76; p-Me (VI), needles, $32-3^\circ$ (petr. ether) (b0.05 $135-6^\circ$), 62; m-Cl (VII), prisms, $57-8^\circ$ (EtOH), 77; p-Cl (VIII), needles, 76 (EtOH), 76; p-Br (IX), needles, 73° (EtOH), 62; o-MeO, needles, $56-7^\circ$, 88; p-MeO, needles, 38° (petr. ether) (b0.1 $160-75^\circ$ with decomposition), 47 (in H_2O); o- PhCH_2O , brown needles, $76-8^\circ$ (ligroine), 74; p- PhCH_2O (X), needles, $73-4^\circ$ (EtOH), 69; p-MeC $_6\text{H}_4\text{SO}_3$, prisms, 106° (EtOH), 72; o- NO_2 , needles, $77-8^\circ$ (EtOH), 91 (in H_2O); p- NO_2 (XI), orange plates, $79-82^\circ$ (EtOAc-ligroine), 82 (in H_2O); p-AcNH (XII), plates, $156-7^\circ$ (C_6H_6), 56; p-EtO $_2\text{CNH}$ (XIII), prisms, $186-7^\circ$ (EtOH), 75. All the compds. were yellow except where noted otherwise. Similarly were prepared the following $\text{ArNHN:CH}(\text{CO}_2\text{Et})_2$ (Ar, crystal form, m.p., and % yield given): 2,3- $\text{Cl}_2\text{C}_6\text{H}_3$, orange plates, $96-7^\circ$, 96; 2,4- $\text{Cl}_2\text{C}_6\text{H}_3$, orange plates, 92° (EtOH), 93; 2,5- $\text{Cl}_2\text{C}_6\text{H}_3$, needles, $90-2^\circ$ (ligroine, b. $60-70^\circ$), 77; 3,4- $\text{Cl}_2\text{C}_6\text{H}_3$, needles, $80-1^\circ$ (EtOH), 74; 3,4-BrMeC $_6\text{H}_3$, prisms, 73° (EtOH), 68° . All the compds. were yellow except where noted otherwise. X (52 g.) in 600 cc. EtOH hydrogenated 7.5 hrs. at $27^\circ/5$ atmospheric over 10 g. 10% Pd-C yielded 28.4 g. p-HOC $_6\text{H}_4\text{NHN:C}(\text{CO}_2\text{Et})_2$, yellow prisms m. $130-1^\circ$ [(CH $_2\text{Cl}$) $_2$]. VI (150 g.) in 280 cc. refluxing EtOH treated dropwise during 0.5 hr. with 280 cc. 2N NaOH, the mixture kept just alkaline to phenolphthalein, the red solution refluxed 10 min., and acidified with 0.5N HCl at room temperature gave 88 g. p-MeC $_6\text{H}_4\text{NHN:C}(\text{CO}_2\text{H})\text{CO}_2\text{Et}$ (XIV), yellow needles m. 141° (decomposition) (EtOH). Similarly were obtained the following p-XC $_6\text{H}_4\text{NHN:C}(\text{CO}_2\text{H})\text{CO}_2\text{Et}$ (X, crystal form, m.p. with decomposition, and % yield given): H (XV), needles, $112-14^\circ$ (EtOH), 62; Cl (XVI), needles, 167° (EtOH), 47; Br, needles, $177-9^\circ$ (AcOH), 13 (isolated as

a by-product in the preparation of IX); MeO, needles, 122-3° (EtOH), 42; PhCH₂O, needles, 122-3° (EtOH) (it formed a very insol. Na salt, m. 168-70°, and K salt, m. 239-40°), 97; p-NO₂ (XVII), orange prisms, 201-2° (EtOCH₂CH₂OH), 66; AcNH (XVIII), needles, 187° (EtOH), 87; EtO₂CNH (XIX), plates, 166-7° (EtOH), 77.

All the compds. were yellow except where noted otherwise. VII (2.3 kg.) in 4.8 l. boiling EtOH treated during 15 min. with stirring with 4.8 l. 2N NaOH, the mixture treated with 19.2 l. N NaOH, refluxed gently 20 min. with stirring, filtered into 2.9 l. concentrated HCl and 8.7 l. H₂O, stirred and

kept

at 35-40° by the addition of 15-20 kg. ice, and filtered gave 1.594 g. m-ClC₆H₄NHN:C(CO₂H)₂, m. 162-4° (decomposition) (EtOAc). Similarly were prepared the following XC₆H₄NHN:C(CO₂H)₂ (X, temperature and time in min. for

the

2nd stage of the hydrolysis, m.p., and % yield given): H (XX), 18°, 150, 162-3° (EtOH), 97; o-Me, 70-80°, 15, 181-2° (aqueous EtOH), 97; p-Me (XXI), 50°, 15, 169-70° (EtOH), 67; o-Cl (XXII), 70-80°, 15, 178-9° (AcOH) (prisms), 90; m-Cl (XXIII), 70-80°, 15, 170° (AcOH), 85; p-Cl, 70-80°, 15, 186-7° (AcOH), 68; p-Br, 70-80°, 10, 91-3° (AcOH), 74; o-MeO (XXIV), 60-5°, 15, 159° (AcOH), 92; p-MeO, 18°, 180, 140-2° (decomposition) (EtOH), 43 (red); o-PhCH₂O, 60-5°, 15, 154-5° (AcOH), 45 [more forcing conditions gave p-PhCH₂OC₆H₄NHN:CHCO₂H, m. 115-16° (decomposition) (EtOH)]; o-MeC₆H₄SO₃, 70-80°, 10, 175° (EtOH), 66; o-NO₂, 70-80°, 10, 195-7° (EtOAc), 72 (orange prisms); p-NO₂ (XXV), 70-80°, 10-15, 199-200° (EtOCH₂CH₂OH), 92 (buff); p-AcNH (XXVI), 35°, 25, 180-1° (H₂O), 90; p-EtO₂CNH, 18°, 210, 175-6° (EtOH), 55 (also 29% diester recovered) (orange rhombs). Similarly were prepared the following ArNHN:C(CO₂H)₂ (Ar, temperature and time

in

min. for 2nd stage of the hydrolysis, m.p., and % yield given): 2,3-Cl₂C₆H₃, 70-80°, 15, 200-2° (AcOH), 83; 2,4-Cl₂C₆H₃, 70-80°, 15, 177-8° (EtOH), 83 (precipitation with N HCl, even at 80°, gave the insol. di-Na salt, converted into the diacid only by stirring with 2N HCl at 85° during 2 hrs.); 2,5-Cl₂C₆H₃, 70-80°, 15, 210-11° (AcOH), 86 (precipitated by the addition of hot concentrated HCl to the hot mixture); 3,4-Cl₂C₆H₃, 70-80°, 10-15, 185-6° (AcOH), 60; 3,4-BrMeC₆H₃ (XXVII), 70-80°, 10, 187-8° (AcOH), 48. PCl₅ (10.025 kg.) added with stirring to 4.98 g. XXII in 16.25 l. dry CHCl₃ at room temperature and the mixture refluxed 1.5

hrs.

gave 4.78 kg. o-ClC₆H₄NHN:C(COCl)₂ (XXVIII), yellow prisms, m. 129-30°. Similarly were prepared the following XC₆H₄NHN:C(COCl)₂ (X, reaction medium, reagent, crystal form, m.p. with decomposition, and % yield given): H (XXIX), CHCl₃, SOCl₂, prisms, 132-5°, 96 [anilide m. 174° (EtOH)]; o-Me, (CH₂Cl)₂, PCl₅, prisms, 145-7°, 86; p-Me, CHCl₃, PCl₅, needles, 143-4°, 71; m-Cl (XXX), CCl₄, PCl₅, needles, 123-4°, 89°; p-Cl, (CH₂Cl)₂, PCl₅, needles, 156-7°, 89 (83% in PhNO₂) [anilide m. 215° (C₆H₆)]; p-Br, CHCl₃, PCl₅, needles, 158-60°, 62; o-MeO (XXXI), C₆H₆, SOCl₂, needles, 172-3°, 83; o-PhCH₂O, CHCl₃, PCl₅, needles, 1213°, 32; o-MeC₆H₄SO₃, C₆H₆, PCl₅, needles, 121-3°, 90; o-NO₂ (XXXII), CHCl₃, PCl₅, needles, 135-7°, 83; p-NO₂, C₆H₆, PCl₅, prisms, 155-6°, 86. The following ArNHN:C(COCl)₂ (Ar, reaction medium, reagent, crystal form, m.p. with decompn., and % yield given): 2,3-Cl₂C₆H₃, CCl₄, PCl₅, needles, 103-4°, 83; 2,4-Cl₂C₆H₃, CHCl₃, PCl₅, plates, 145-6°, 58; 2,5-Cl₂C₆H₃, CCl₄, PCl₅, prisms,


110-11°, 50; 3,4-Cl₂C₆H₃, CHCl₃, SOCl₂, needles, 149-50°, 63. All the compds. were yellow. 5,2-Cl(O₂N)C₆H₃CHBrCHBrCO₂H (10 g.) added with stirring to 40 cc. 10% aqueous NaOH, warmed at 40-5 to solution, kept 3 hrs. at room temperature, and poured into 50 cc. 2N H₂SO₄ yielded 5.0 g. 5,2-Cl(O₂N)C₆H₃C.tplbond.CCO₂H, needles, m. 135° (decomposition). TiCl₄ (1.975 l.) added with stirring to 4.78 kg. XXVIII in 27.5 l. dry C₆H₆ while being cooled to 95°, the mixture heated 6 hrs. at 95°, treated with 5.5 kg. NaOH in 69 l. H₂O, steam distilled, filtered, the residue washed with hot H₂O, the combined filtrate and washing acidified, and the crude precipitate dissolved in 45 l. 2N NH₄OH, filtered, and reprecipitated. gave 3.464 kg. 8-chloro-4-hydroxycinnoline-3-carboxylic acid, m. 247-8° (decomposition). Similarly were prepared the following substituted I (substituent, color, m.p. with decomposition, and % yield given): H, fawn, 267-8° (AcOH), 77; 8-Me, colorless, 263-4° (AcOH), 92; 6-Me, fawn, 269 (HCONMe₂), 87; 5-Cl (from XXX), silvery plates, 263-4° (HCONMe₂), 63; 6-Cl, colorless, 267° (HCONMe₂), 96; 6-Br, yellow, 256-8° (HCONMe₂), 83; 6-MeO, fawn, 258-9° (AcOH), 76; 8-(p-MeC₆H₄SO₃), colorless, 255° (AcOH), 5; 6-NO₂, yellow, 275° (AcOH), 20. The following disubstituted I (substituents, color, m.p. with decomposition, and % yield given): 7,8-di-Cl, colorless prisms, 249-50°, 68 (80% of the product separated during the reaction as a PhNO₂-insol. TiCl₄ complex which was filtered off and decomposed with boiling N NaOH, which was acidified to deposit the product); 6,8-di-Cl, fawn, 250-1° (AcOH), 27 (reaction time 21 hrs.); 5,8-di-Cl, fawn, 248-9° (AcOH), 11; 5,6-di-Cl, fawn, 268° (AcOH), 46; 5(or 7)-Br and 6-Me, fawn, 262-3° (HCONMe₂), 40 (from crude acid chloride prepared in situ by treating XXVII with SOCl₂ in C₆H₆ and evaporating in vacuo) (all compds. crystallized as needles except where noted otherwise). XXXII (67 g.) and 32.5 cc. TiCl₄ in 350 cc. dry PhNO₂ heated 8 hrs. at 95°, poured into 4.5 l. boiling H₂O, steam distilled to remove the PhNO₂, filtered, cooled, the yellow solid (32 g.) dried and extracted with 400 cc. boiling EtOAc left 5 g. 4-hydroxy-8-nitrocinnoline-3-carboxylic acid, pale green needles, m. 253-4° (decomposition). TiCl₄ (420 cc.) added during 20 min. to 858 g. XXIX in 3.5 l. dry (CH₂Cl)₂, the mixture heated 7 hrs. on the steam bath, evaporated in vacuo, the residue powdered, extracted with hot 4N NaOH, the combined exts. acidified, a 400-g. portion of the crude product (757 g.) stirred 18 hrs. at 15° with 800 cc. concentrated HNO₃, and poured on ice yielded 809 g. 4-hydroxycinnoline-3-carboxylic acid, m. 267-8° (AcOH). 5-Chloro-4-hydroxycinnoline (64 g.), 84 g. PCl₅, and 250 cc. POCl₃ stirred 1 hr. at 95°, cooled, filtered, the residual 4,5-dichlorocinnoline-HCl (71.3 g.) added during 5 min. to dry PhOK (from 44 g. KOH and 300 g. PhOH) in 2 l. dry C₆H₆ at 70-80°, the mixture evaporated in vacuo, the residue heated 1 hr. on the steam bath, cooled, extracted with CHCl₃, and the extract worked up yielded 53.5 g. 5-chloro-4-phenoxy-cinnoline (XXXIII), brown needles, m. 118-19° (ligroine, b. 100-20). 4-Amino-5-chlorocinnoline, fawn needles, m. 178-9°, was prepared by the method of Keneford, et al. (CA 42, 5031b). 5,6-Dichloro-4-hydroxycinnoline (1.1 g.) and 5.5 cc. Ac₂O refluxed 1 hr., poured onto ice, and filtered gave 1 g. acetate (XXXV), prisms, m. 178-9° (ligroine, b. 80-100). XXXIV (1.5 g.), 1.5 g. PCl₅, and 4 cc. POCl₃ heated 1.5 hrs. on the steam bath, the resulting 4,5,6-trichlorocinnoline-HCl (1.4 g.) filtered off, heated 1 hr. with 3 g. PhOH and 0.5 g. powdered KOH at 95°, cooled, mixed with excess 2N NaOH, and extracted with CHCl₃ yielded 1.45 g. 4-PhO analog of XXXV, needles, m. 189° (ligroine). The appropriate substituted I in Ph₂CO 4 parts

heated 0.5-1 hr. at 180-210° until the CO₂ evolution ceased, extracted with Et₂O or ligroine (b. 80-100°), evaporated, the residue dissolved in boiling N Na₂SO₃, and the solution acidified gave the corresponding 4-hydroxycinnoline (XXXVI); method A. The crude reaction mixture extracted directly with boiling N Na₂CO₃ and the extract acidified gave the corresponding XXXVI; method B. On a larger scale the decarboxylation was performed in boiling Dowtherm. In this manner were prepared the following substituted XXXVI (substituents, method, color, m.p., and % yield given): none, -(in Dowtherm), colorless, 236-7° (EtOH), 82; 8-Me, A, fawn, 219-21° (repptd.), 56; 6-Me, A, fawn, 271° (AcOH), 64; 8-Cl, B, colorless, 198-9° (AcOH), 74; 5-Cl, A, fawn, 330-2° (HCONMe₂), 70; 6-Cl, B, fawn, 296° (EtOH), 85; 7,8-di-Cl, A, colorless, 261-2° (AcOH), 95; 6,8-di-Cl, A, gray, 221-3° (AcOH), 90; 5,8-di-Cl, A, colorless, 222-4° (AcOH), 70; 5,6-di-Cl, A, fawn, 336-7° (AcOH), 65; 6-Br, A, fawn, 277-8° (EtOH), 45; 5(or 7)-Br and 6-Me, A, colorless, 288-9° (EtOCH₂CH₂OH), 45; 8-MeO, A, colorless, 162-3° (H₂O), 96; 6-MeO, -(in Dowtherm), gray plates, 254-5° (MeOH), 31 (precipitated from BzPh with Et₂O and extracted with H₂O); 6-NO₂, A, yellow prisms, m. 336° (AcOH), 70. All the compds. were needles unless otherwise stated. II (4.35 g.) and 4.95 g. 2,4-(O₂N)₂C₆H₃NHNH₂ in 100 cc. AcOH heated 2 hrs. at 95°, cooled, poured with stirring into 800 cc. iced H₂O, the solid filtered off, washed with H₂O, a 2-g. portion of the residue (7.4 g.) extracted with 600 cc. boiling ligroine, b. 60-80°, filtered, and cooled gave 1.3 g. 2,4-(O₂N)₂C₆H₃NHN:C(CO₂Et)₂, bright yellow prisms, m. 116-17°. o-MeOC₆H₄NH₂ (62.5 g.) diazotized in the usual manner, added with stirring at 20° to 66 g. CH₂(CO₂Me)₂, 150 g. NaOAc, 1 l. MeOH, and 400 cc. H₂O, and worked up gave 101 g. o-MeOC₆H₄NHN:C(CO₂Me)₂ (XXXVII), yellow plates, m. 111-12° (MeOH). Similarly were prepared the following XC₆H₄NHN:C(CO₂Et)CN (X, m.p., % yield, and starting material used given): H (XXXVIII), 124-5° (C₆H₆), 93, NCCH₂CO₂Et (XXXIX); p-Cl, 157-8° (α-form, precipitated from an alkaline solution by 2N HCl) [124-5° (β-form, precipitated from an alkaline solution by CO₂)], 96, XXXIX; p-MeO (XL), 120° (α-form, precipitated with 2N HCl) [81-2° (aqueous EtOH) (β-form)], 98, XXXIX; p-AcNH (XLI), 210° (50% aqueous C₅H₅N), 75, XXXIX. The following XC₆H₄NHN:CAB (X, A, B, m.p., % yield, and starting material used given): p-Me, CO₂Me, CO₂Me (XLII), 84-5° (MeOH), 78, CH₂(CO₂Me)₂; p-Cl, CN, CN (XLIII), 187° (EtOH), 66, CH₂(CN)₂; H, CO₂Et, NO₂, 60-1° (petr. ether), 56, O₂NCH₂CO₂Et (as the NH₄ salt); p-Cl, CO₂Et, NO₂, 118-19° (EtOH), 40, O₂NCH₂CO₂Et; p-Cl, Ac, Ac (XLIV), 132-3° (EtOH), 96, Ac₂CH₂; p-MeO, Ac, Ac (XLV), 100-1° (EtOH), 96, Ac₂CH₂. XLII (50 g.) in 100 cc. refluxing MeOH treated with 81 cc. 2.46N NaOH-MeOH, refluxed briefly, cooled, diluted with Et₂O, filtered, the residue ground with excess 2N HCl, and filtered gave 24 g. p-MeC₆H₄NH N: C(CO₂)CO₂Me (XLVI), m. 153-4° (MeOH). XLVI (20 g.) heated at 165° until the CO₂ evolution ceased, the cold residue triturated with excess petr. ether, and filtered gave 5.1 g. α-form of p-MeC₆H₄NHN:CHCO₂Me (XLVIII), m. 174-5° (MeOH); the filtrate evaporated and the residual sirup triturated with MeOH at -40° gave 9.5 g. β-form of XLVIII, m. 21-2° (light petroleum). XVI (20 g.) heated at 178° until the CO₂ evolution ceased, cooled, and diluted with petr. ether gave 14.7 g. (crude) p-ClC₆H₄NHN:CHCO₂Et (XLIX), which crystallized from EtOAc-ligroine (b. 60-80°) gave the pure α-form, m. 151-2°; crystallization from EtOH yielded the β-form, m. 68-9°, identical with the product obtained in 16% yield after dry distillation of the crude product from diazotized p-ClC₆H₄NH₂ and CH₂(CO₂K)CO₂Et. XL (26.8 g.) in 108 cc. 2N HCl heated 80 min. at 65-70° with 324 cc. 2N NaOH, cooled, kept at room temperature overnight, acidified with 2N HCl, and the precipitate (24.7 g.) extracted with

500 cc. boiling ligroine, b. 60-80°, yielded 22.7 g. p-MeOC₆H₄NHN:C(CN)CO₂H (L), m. 154-5° (AcOH), which on recrystn. from aqueous EtOH was decarboxylated to p-MeOC₆H₄NHN:CHCN, m. 127-8°. Similarly was prepared the p-Cl analog of L, m. 160-1° (EtOH). p-ClC₆H₄NHN:CHCO₂Et (109.3 g.) in 242 cc. refluxing absolute EtOH treated with 242 cc. 2.4N alc. NaOH, the mixture refluxed 20 min., cooled to 0°, and filtered gave 40 g. Na salt, pale yellow needles, m. 259-63° (decomposition) (EtOH), which acidified with iced 2N HCl gave 9% p-ClC₆H₄NHN:CHCO₂H, m. 134-5°. The appropriate acid of the type p-RC₆H₄NHN:C(CO₂H)B heated with SOCl₂ in C₆H₆ or CHCl₃ gave the corresponding p-RC₆H₄NHN:C(COCl)B (R, B, m.p., % yield, and solvent used given): Me, CO₂Et, 76°, 45, C₆H₆; Cl, CN(LI), 151-4°, 65, C₆H₆ [anilide m. 218-19° (EtOH)]; MeO, CN (LIa), 138-40°, 68, CHCl₃ [anilide m. 167-9° (EtOH)]; Cl, H (LII), 127-8°, 49, CHCl₃; PhCH₂O, CO₂Et (LIII), 105-7°, 85, none (Na salt of acid treated with SOCl₂). XIV (25 g.) treated with 13 g. SOCl₂ in 700 cc. dry C₆H₆, the mixture evaporated in vacuo at 50°, dissolved in 200 cc. dry PhNO₂, heated 2 hrs. at 95° with 27.4 g. SnCl₄, divided into 4 equal portions, 1 portion treated with 190 cc. 1.95N NaOH, steam distilled to remove the PhNO₂, filtered, and acidified hot with 45 cc. concentrated HCl yielded 2.7 g. crude 4-hydroxy-6-methylcinnoline-3-carboxylic acid, m. 265-6° (AcOH). LIII gave similarly at 95° during 3.75 hrs. only 5% low-melting acid, LII gave similarly 18% low-melting acid during 6 hrs., LI yielded 17% in 5 hrs., and LIa 2.5% in 6 hrs. LI, XLII, V, VIII, VI, XI, XII, XLVIII, LXIX, and XIV subjected to cyclization in Dowtherm at 250-60° or BzPh at 297° resulted in a complete breakdown with the evolution of MeOH or EtOH and HCN. XIII gave similarly 46% p-EtO₂CNHC₆H₄NCO, m. 64-5° (petr. ether), which yielded with EtOH p-C₆H₄(NHOCOEt)₂, m. 193-4° (EtOH). XIV, XIX, XXIV, XLIV, and XLV treated with concentrated H₂SO₄ gave at room temperature unchanged starting material or sulfonation product and at 60-95° resulted in sulfonation and (or) decomposition XXXVIII and XLI treated with concentrated H₂SO₄ at room temperature gave starting material or sulfonation product. XLIII yielded similarly the monoamide, m. 266° (AcOH). VIII, XV, XVI, XIV, XVIII, XX, XXI, XXIV, XXV, XLIII, and XLIV treated with polyphosphoric acid at 45-100° gave only unchanged starting material and at 100-65° decomposition products. XIII treated at 60-95° with concentrated H₂SO₄ and Ac₂O gave the monosulfo derivative of XIII, isolated in low yield as the Na salt. VIII treated at 110-20° with Et₂O.BF₃ gave the BF₃ complex, m. 193-4°, which with AcOH yielded XVI, m. 171°. XVII, XIV, XX, and XXI refluxed with POCl₃ gave some unchanged starting material and intractable by-products. XXI and XXVI treated at 0-15° with anhydrous HF and XXIII treated at 40 with FSO₃H gave only unchanged starting materials.

L8 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1959:56393 CAPLUS
 DOCUMENT NUMBER: 53:56393
 ORIGINAL REFERENCE NO.: 53:10186g-i,10187a-c
 TITLE: Thiazole derivatives as antispasmodics and antihistaminics. III
 AUTHOR(S): Tripathy, Pranabandhu; Pujari, H. K.; Rout, M. K.
 CORPORATE SOURCE: Ravenshaw Coll., Cuttack
 SOURCE: J. Indian Chem. Soc. (1958), 35, 407-10
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable


IT 101865-38-7, Thiazole, 2-acetamido-5-(diethylaminomethyl)-4-phenethyl-
phenethyl-
(preparation of)
RN 101865-38-7 CAPLUS
CN Thiazole, 2-acetamido-5-(diethylaminomethyl)-4-phenethyl- (6CI) (CA INDEX
NAME)




AB Thiazoles were condensed with HCHO and different ketones, quinolines, or pyrazolones. Thus, 1.76 g. 4-phenyl-2-aminothiazole (I), 1.2 g. PhCOMe, and 0.9 g. paraformaldehyde (II) in 3 ml. concentrated HCl and 2.5 ml. EtOH was refluxed 2 hrs., 0.6 g. addnl. II added, the mixture refluxed 3 hrs., the alc. distilled, the pasty mass treated with NH4OH until solidification (2-3 hrs.), the solid washed with H2O, and recrystd. from EtOH to yield 82% 2-(3-oxo-3-phenylpropylamino)-4-phenylthiazole, m. 115°. Similarly, the following thiazoles (R in 4-position, R' of NHCH2R' in 2-position, and m.p. given) were prepared in 70- 88% yield: Ph, CH2CH2COC6H4OH-p, 78°; Ph, CH2COC6H4OH-p, 89°; Ph, CH2COCH:CHPh, 103°; Ph, CH2COC6H3(OMe)OH-p, 81°; Ph, CH2COC6H4OMe-p, 86°; PhCH2CH2, CH2Bz, 145°; p-HOC6H4, CH2Bz, 180° (decomposition); p-HO(MeO)C6H3, CH2Bz, 160° (decomposition); β-C10H7, CH2Bz, 132°. I (1.76 g.), 1.2 g. II, and 1.73 g. 1-phenyl-3-methyl-5-pyrazolone (III) in 3 ml. concentrated HCl and 25 ml. EtOH was refluxed over asbestos-wire gauze 8 hrs., the alc. distilled, the mass poured into H2O, the gummy product hardened in contact with concentrated NH4OH, dissolved in NaOH, and repptd. with HOAc to yield 85% 2-(1-phenyl-3-methyl-5-oxo-4-pyrazolinylmethylamino)-4-phenylthiazole, m. 121°. Similarly, the 2-(1-phenyl-3-methyl-5-oxo-4-pyrazolinylmethylamino)-4-arylthiazoles (aryl and m.p. given) were prepared in 65-85% yield: 4,3-HO(MeO)C6H3, 180° (decomposition); PhCH2CH2, 145-6°; p-HOC6H4, 160° (decomposition); β-C10H7, 158°. Similarly, the condensation of III with 2-amino-4,5,6,7-tetrahydrobenzothiazole gave 2-(1-phenyl-3-methyl-5-oxo-4-pyrazolinylmethylamino)-4,5,6,7-tetrahydrobenzothiazole, m. 102° (decomposition). III and 8-hydroxyquinoline gave 2-(8-hydroxy-7-quinolinylmethylamino)-4-phenylthiazole, m. 101°. To 2.1 g. 2-acetamido-4-phenylthiazole 0.6 g. Et2NH in 5 ml. HOAc and 1 ml. formalin was added, the mixture refluxed 8 hrs., diluted with 10 ml. H2O, treated with saturated K2CO3, the precipitate filtered off, washed with H2O, and recrystd. from EtOH to yield 75% 2-acetamido 4-phenyl-5-(diethylaminomethyl)thiazole, m. 80°. Similarly, the following 2-acetamido-4-aryl-5-(diethylaminomethyl)thiazoles (aryl, m.p. given) were prepared in 80-85% yield: PhCH2CH2, 188° (decomposition); β-C10H7, 245° (decomposition).

L8 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1956:4689 CAPLUS
DOCUMENT NUMBER: 50:4689
ORIGINAL REFERENCE NO.: 50:963e-i,964a-b
TITLE: 4-Styrylthiazoles. Syntheses and relationships among
ultraviolet absorption spectra
AUTHOR(S): Southwick, Philip L.; Sapper, David I.

CORPORATE SOURCE: Carnegie Inst. of Technol., Pittsburgh, PA
 SOURCE: Journal of Organic Chemistry (1954), 19, 1926-37
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 50:4689
 IT 93044-41-8, Thiazole, 2-acetamido-5-nitro-4-styryl-
 859969-74-7, Thiazole, 2-acetamido-4-styryl-
 (preparation of)
 RN 93044-41-8 CAPLUS
 CN Acetamide, N-[5-nitro-4-(2-phenylethenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 859969-74-7 CAPLUS
 CN Thiazole, 2-acetamido-4-styryl- (5CI) (CA INDEX NAME)




GI For diagram(s), see printed CA Issue.
 AB A number of 4-styrylthiazoles, $\text{PhCH:CHC:CR.S.CR':N}$ (I), have been prepared and their ultraviolet absorption spectra studied. Adding 12.5 g. PhCH_2COMe to 10.2 g. BzH and 0.75 g. NaOH in 400 cc. H_2O at $58-60^\circ$ with stirring and stirring the mixture 18-20 hrs. at 60° give 50-60% benzyl styryl ketone (II), m. $69-73^\circ$. Adding 21.6 g. Br to 15 g. II in 30 cc. hot CCl_4 and adding another 30 cc. CCl_4 give 54.5% 1,3,4-tribromo-1,4-diphenyl-2-butanone (III), m. $126-8^\circ$. Treating 10 g. III in 40 cc. Me_2CO with 9.9 g. NaI in 60 cc. Me_2CO and warming the mixture to 50° give 55% 1-iodo-1,4-diphenyl-3-buten-2-one (IV), m. $91.5-3^\circ$. Heating 0.75 g. iodomethyl styryl ketone (V) in 4 cc. EtOH with 0.25 g. $\text{HCSNH}_2 \cdot \text{H}_2\text{O}$ in 4 cc. EtOH 1 hr. on a steam bath, making the mixture alkaline with NaOH , extracting with Et_2O , and treating the residue of the ether extract with picric acid give 8% 4-styrylthiazole picrate, yellow prisms, m. $163-6^\circ$. Similarly 2 g. V and 0.55 g. MeCSNH_2 refluxed 1 hr. in 10 cc. EtOH and kept 2 days at 20° give 19% 2-methyl-4-styrylthiazole (VI) picrate, yellow plates, m. $177-80^\circ$ [HCl salt, m. $146-52^\circ$]. Refluxing 3 g. 1-bromo-1,4-diphenyl-3-buten-2-one and 0.75 g. MeCSNH_2 in 10 cc. absolute EtOH 2 hrs. gives 24% 2-methyl-4-styryl-5-phenylthiazole- HCl , m. $145-55^\circ$ (decomposition). Warming 2 g. V with 0.56 g. $\text{CS}(\text{NH}_2)_2$ in 10 cc. EtOH and keeping the mixture overnight at -10° give 57.5% 2-amino-4-styrylthiazole (VII).HI, cubes, crystallizing with 1 EtOH , m. $181-1.5^\circ$ (free base, pale yellow needles, m. $160-2^\circ$). Heating 3 g. IV and 0.66 g. $\text{CS}(\text{NH}_2)_2$ 1.5 hrs. in 15 cc. EtOH gives 48.2% 2-amino-4-styryl-5-phenylthiazole, yellow plates, m. $160-1.5^\circ$, which is also prepared in 38% yield by refluxing 5 g. II, 5.7 g. iodine, and 6 g. $\text{CS}(\text{NH}_2)_2$ in 20 cc. EtOH 12 hrs. (HI salt, needles, m. $217-28^\circ$). Treating 2 g. IV with 0.66 g. $\text{CS}(\text{NH}_2)\text{SNH}_4$ (VIII)

gives 28% 2-mercapto-4-styryl-5-phenylthiazole, light yellow needles, m. 224-5°. Similarly, 2 g. V and 0.88 g. VIII in 20 cc. EtOH give 49% 2-mercapto-4-styrylthiazole, yellow prisms, m. 210-11.5°. Treating 2 g. V with 32 g. Ba(CNS)2.SH2O (IX) in 15 cc. EtOH gives 67% thiocyanomethyl styryl ketone, plates, m. 118.5-19.5° which (0.6 g.), heated 5 hrs. with 12 cc. 3N HCl, gives 2-hydroxy-4-styrylthiazole, prisms, m. 211-14°. Refluxing 2.5 g. IV and 1.2 g. IX 5 hrs. in EtOH, extracting the mixture with Et2O, and heating the residue of the ether extract

1.5 hrs. with 10 cc. AcOH and 1 cc. concentrated HCl give 20% 2-hydroxy-4-styryl-5-phenylthiazole, pale yellow needles, m. 227-9°. Heating 2.1 g. VII 0.5 hr. in 20 cc. Ac2O gives 85% 2-acetamido-4-styrylthiazole, plates, m. 205.5-6.5°, which (0.9 g.), treated with 10 cc. concentrated HNO3, gives 38% 2-acetamido-4-styryl-5-nitrothiazole, deep yellow needles, m. 261-2°; when this is oxidized with CrO3 in AcOH a small amount of BzOH is formed. The ultraviolet spectrum of VI shows a close resemblance to that of trans-stilbene or of 2- and 4-stilbazole. The effects on the ultraviolet spectrum of I with a NH2, SH, or OH in the 2-position and of the Ph group in the 5-position of the thiazole ring have been found to parallel in many respects the effects produced by the corresponding groups in derivs. of aromatic hydrocarbons.

L8 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1951:16499 CAPLUS
DOCUMENT NUMBER: 45:16499
ORIGINAL REFERENCE NO.: 45:2934d-h
TITLE: Reaction of ketones with iodine and thiourea
AUTHOR(S): King, L. Carroll; Hlavacek, Robert J.
CORPORATE SOURCE: Northwestern Univ., Evanston, IL
SOURCE: Journal of the American Chemical Society (1950), 72, 3722-5
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 45:16499
IT 859463-48-2, Thiazole, 2-acetamido-4-benzyl-5-phenyl-
(preparation of)
RN 859463-48-2 CAPLUS
CN Thiazole, 2-acetamido-4-benzyl-5-phenyl- (5CI) (CA INDEX NAME)



AB cf. C.A. 42, 6360f. The ketone (0.1 mol.), 0.2 mol. CS(NH2)2, and 0.1 mol. iodine, heated overnight on the steam bath, give the substituted 2-aminothiazole; the cooled reaction product is extracted with ether, the residue in boiling H2O filtered, the filtrate made alkaline with concentrated NH4OH, and the precipitate crystallized from aqueous EtOH; if the product is an oil, it is crystallized from Skellysolve C. The m.ps. of the Ac derivs. are given in parentheses. 4-Substituted 2-aminothiazoles: p-chlorophenyl, m. 163-4°, 89% [254-5°]; p-bromophenyl, m. 180-1°, 93%

[277-8°]; p-iodophenyl, m. 176-7°, 97% [302-3°]; p-methoxyphenyl, m. 204-5°, 72% [287-8°]; p-(methylmercapto)phenyl, m. 180-2°, 67% [232-3°]; p-aminophenyl, m. 174-5°, 63% [di-Ac derivative, m. 284-6°]; p-biphenyl, m. 207-8°, 99% [252-3°]; p-tolyl, m. 124-5°, 84% [204-5°]; m-isomer, m. 79-92°, 64% [211-12°]; o-isomer, m. 81-2°, 70% [143-4°]; p-nitrophenyl, m. 285-6°, 99% [306-7°]; m-isomer, m. 188-90°, 84% [312-14°]; 2-naphthyl, m. 153-4°, 99% [239-40°]; 2-phenanthryl, m. 243-4°, 87% [304-5°]; 2-thienyl, m. 127-30°, 91% [199-207°]; tert-Bu, m. 98-9°, 71% [173-4°]; o-hydroxyphenyl, m. 139-40°, 37% [di-Ac derivative, m. 200-3°; HI salt, m. 220-3° (each HI salt has 1 mol. H₂O)]; m-isomer, m. 136-8°, 59% [di-Ac derivative, 186-7°; HI salt, 95-7°]; p-isomer, m. 198-200°, 62% [di-Ac derivative, m. 235-7°; HI salt m. 240-2°]; 4-phenyl-5-Et, m. 68-9°, 65% [175-6°]; 4-phenyl-5-Bu, m. 103-4°, 54% [135-6°]; 4-phenyl-5-Bu, m. 60-1°, 43% [187-8°]; 4-benzyl-5-Ph, m. 139-40°, 83% [164-5°]; 4,5-di-Ph, m. 184-5°, 99% [208-9°]; 4-phenyl-5-benzoyl, m. 215-16°, 18% [237-8°]. The aminothiazole from 4-methylcyclohexanone, C₈H₁₂N₂S, m. 98-9°, 66% [162-3°]; the 3-isomer gives 24% 2-amino-5(or -7)-methyl-4,5,6,7-tetrahydrobenzothiazole, m. 110-11° [150-1°]. Compound from cycloheptanone, C₈H₁₂N₂S, m. 75-6° 60% [124-5°]; from hydrindone, C₁₀H₈N₂S, m. 213-14°, 53% [284-5°]; from 3,4-dihydro-1(2H)-naphthalenone, m. 133-4°, 52% [233-4°]; acenaphthenone gives 99% 8-aminoacenaphtho-1,2-thiazole, bright red, m. 205-7° [309-11°]. Bromoacetomesitylene (4.6 g.) yields 3.8 g. 2,4,6-trimethylphenacylisothiuronium bromide, m. 280-2°; it could not be cyclized to a thiazole.

L8 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1951:13861 CAPLUS

DOCUMENT NUMBER: 45:13861

ORIGINAL REFERENCE NO.: 45:2474d-g

TITLE: Bacteriostatic sulfones. I. Bis(2-amino-4-substituted-5-thiazolyl) sulfones

AUTHOR(S): Libermann, D.; Moyeux, M.

SOURCE: Bulletin de la Societe Chimique de France (1950) 301-4
CODEN: BSCFAS; ISSN: 0037-8968

DOCUMENT TYPE: Journal


LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 45:13861

IT **859481-76-8**, Thiazole, 5,5'-thiobis[2-acetamido-4-benzyl-
(preparation of)

RN 859481-76-8 CAPLUS

CN Thiazole, 5,5'-thiobis[2-acetamido-4-benzyl- (5CI) (CA INDEX NAME)



AB Bis(2-acetamido-4-methyl-5-thiazolyl) sulfide (15 g.) in 120 cc. glacial AcOH at 60-70° treated gradually with stirring with 15 cc. 30% H₂O₂ gave 11 g. of the di-Ac derivative (I), m. above 350°, of bis(2-amino-4-methyl-5-thiazolyl) sulfone (II). I (11 g.) boiled with 60 cc. AcOH and 40 cc. 6 N HCl gave 6 g. II, m. 248° (decomposition; from 50% MeOH). Similar oxidation of 17 g. bis(2-acetamido-4-propyl-5-thiazolyl) sulfide gave first 15 g. of the sulfoxide, m. 193° (from MeOH), which was oxidized by a further H₂O₂ treatment to 8 g. of the di-Ac derivative (III), m. 260°, of bis(2-amino-4-propyl-5-thiazolyl) sulfone (IV). III heated 15 min. with 800 cc. 18% HCl gave 4 g. IV, m. 219° (from 50% EtOH). PhCH₂CN (50 g.) in 250 cc. absolute EtOH saturated with HCl gas at 0°, let stand overnight, evaporated to dryness in vacuo, and the residue boiled 30 min. with 100 cc. EtOH, 17 cc. H₂O, and 3 cc. concentrated HCl, gave 46 g. (71%) Et α-phenylacetoacetate, b₅ 127-30°. This in 130 cc. CS₂ treated with cooling with 36 g. Br yielded 45 g. BrCH₂COCHPhCO₂Et which, shaken 12 hrs. with 18 g. SC(NH₂)₂ and 200 cc. H₂O, gave 18 g. Et 2-amino-α-phenyl-4-thiazoleacetate, m. 157° (from 95% EtOH). This, boiled 90 min. with 6 g. NaOH in 120 cc. 95% EtOH, gave 14 g. of the corresponding Na salt, which, boiled 1 day with 15 cc. concentrated HCl and 60 cc. H₂O, gave 9 g. 2-amino-4-benzylthiazole, m. 96-7° (from C₆H₆-petr. ether). This (19 g.) with 11.5 g. SC(NH₂)₂ and 25 g. iodine in 170 cc. 50% EtOH gave 16 g. bis(2-amino-4-benzyl-5-thiazolyl) sulfide, m. 190° (di-Ac derivative, m. 253° (from Ac₂O)). H₂O₂ oxidation of 11 g. Ac derivative in 2 steps as above gave 3 g. 5,5'-bithiazole, m. 261°.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
108.23	447.38

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-15.75	-15.75

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:22:23 ON 07 FEB 2006

10/764,529

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal20ltxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:27:46 ON 07 FEB 2006

10/764,529

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:28:00 ON 07 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

DICTIONARY FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107645293.str



chain nodes :

10/764,529

6 7 8 9 10 18 19 20 21
ring nodes :
1 2 3 4 5 12 13 14 15 16 17
chain bonds :
2-6 5-18 6-7 6-9 7-8 7-10 13-19 18-19 18-21 19-20
ring bonds :
1-2 1-5 2-3 3-4 4-5 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
1-2 1-5 2-6 6-7 7-8 13-19 18-19 18-21
exact bonds :
2-3 3-4 4-5 5-18 6-9 7-10 19-20
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 12:28:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 132 TO 668
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 12:28:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 335 TO ITERATE

100.0% PROCESSED 335 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

L3 7 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 12:28:32 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 4 L3

=> d l4 ibib hitstr abs 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1042064 CAPLUS

DOCUMENT NUMBER: 143:332555

TITLE: Aqueous composition comprising thiazole derivative

INVENTOR(S): Ueno, Ryuji; Hirata, Ryu; Harada, Yasuhiro

PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089755	A1	20050929	WO 2005-JP5607	20050318
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-553956P P 20040318

OTHER SOURCE(S): MARPAT 143:332555

IT 737823-01-7


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation and stability of aqueous composition comprising thiazole derivative)

RN 737823-01-7 CAPLUS

10/764,529

CN 4-Thiazolecarboxamide, 2-(acetlamino)-N-[4-[(aminoiminomethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



AB The present invention provides an aqueous composition comprising a thiazole derivative or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alc., boric acid or its salt, and water. The aqueous composition is very stable and can be stored for

a long time. For example, a 0.3% aqueous solution of N-[4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl]acetamide (I) (pH 6) was prepared using HCl acid and an additive selected from glycerin 2.5%, mannitol 4.7%, or boric acid 1.68%. The solution was stored at 40° in the low-d. polyethylene container. The concentration of the thiazole compound I after 1 mo, 3 mo, and 6 mo was 105.4, 110.6 and 112.3% of the original 100% concentration of I for glycerin, 103.7, 108.4 and 109.6% for mannitol, and 104.9, 106.2, and 108.2% for boric acid, resp.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857384 CAPLUS

DOCUMENT NUMBER: 141:350160

TITLE: treatment of vascular hyperpermeable disease using acylaminothiazoles and related compounds as vascular adhesion protein-1 (VAP-1) inhibitors.

INVENTOR(S): Ueno, Ryuji; Nagashima, Akira; Inoue, Takayuki; Ohkubo, Mitsuru; Yoshihara, Kousei

PATENT ASSIGNEE(S): Sucampo Ag, Switz.; Fujisawa Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 269 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087138	A1	20041014	WO 2004-JP4596	20040331
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,			

10/764,529

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

CA 2520957 AA 20041014 CA 2004-2520957 20040331

EP 1608365 A1 20051228 EP 2004-724735 20040331

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: US 2003-458370P P 20030331

WO 2004-JP4596 W 20040331

OTHER SOURCE(S): MARPAT 141:350160


IT 737823-01-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(treatment of vascular hyperpermeable disease using acylaminothiazoles
and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)

RN 737823-01-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-[4-[(aminoiminomethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




IT 737823-02-8P 737823-03-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(treatment of vascular hyperpermeable disease using acylaminothiazoles
and related compds. as vascular adhesion protein-1 (VAP-1) inhibitors)

RN 737823-02-8 CAPLUS


CN Carbamic acid, [4-[[[2-(acetylamino)-4-thiazolyl]carbonyl]amino]phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 737823-03-9 CAPLUS


CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-(4-aminophenyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

10/764,529



● HCl

GI



AB A method for treating a vascular hyperpermeable disease (except macular edema), comprises administration of a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. Thus, N-[4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-2-yl]acetamide (preparation given) was refluxed with HCl and cyanamide in EtOH for 26 h to give title compound (I). I inhibited human plasma VAP-1 (SSAO) with IC50 = 0.15 μ M.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:648516 CAPLUS

DOCUMENT NUMBER: 141:190785

TITLE: Preparation of thiazole derivatives as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases

INVENTOR(S): Inoue, Takayuki; Tojo, Takashi; Morita, Masataka; Ohkubo, Mitsuru; Yoshihara, Kousei; Nagashima, Akira

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067521	A1	20040812	WO 2004-JP708	20040127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			

10/764,529

CA 2514573	AA	20040812	CA 2004-2514573	20040127
US 2004259923	A1	20041223	US 2004-764529	20040127
EP 1587800	A1	20051026	EP 2004-705519	20040127

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:
US 2003-442509P P 20030127
US 2003-458369P P 20030331
US 2003-517377P P 20031106
WO 2004-JP708 W 20040127

OTHER SOURCE(S): MARPAT 141:190785


IT **737823-01-7P**, 2-(Acetylamino)-N-[4-[[amino(imino)methyl]amino]phenyl]thiazole-4-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(VAP-1 inhibitor; preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)

RN 737823-01-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-[4-[(aminoiminomethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




IT **737823-02-8P**, tert-Butyl [4-[[[2-(acetylamino)thiazol-4-yl]carbonyl]amino]phenyl]carbamate **737823-03-9P**, 2-(Acetylamino)-N-(4-aminophenyl)thiazole-4-carboxamide hydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases)


RN 737823-02-8 CAPLUS

CN Carbamic acid, [4-[[[2-(acetylamino)-4-thiazolyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 737823-03-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-(4-aminophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



II

AB Title compds. of formula R₁NHXYZ [I; wherein R₁ = acyl; X = a bivalent (un)substituted thiazole; Y = a bond, alkylene, alkenylene, COHN; Z = 2-aminobenzimidazolyl, C₆H₄-R₂; R₂ = ABDE; A = a bond, alkylene, NH, SO₂; B = a bond, alkylene, CO, O; D = a bond, alkylene, NH, CH₂NH; E = (un)protected amino, N=CH₂, dihydrothiazol-2-yl, dihydroimidazol-2-yl, C(=NH)R₃; R₃ = H, alkyl(thio), NHR₄; R₄ = H, NH₂, alkyl; and pharmaceutically acceptable salts thereof] were prepared as vascular adhesion protein-1 (VAP-1) inhibitors. For example, cycloaddn. of 3-chloro-2-oxopropyl acetate and thiourea in EtOH gave (2-amino-1,3-thiazol-4-yl)methyl acetate•HCl, which was amidated with acetyl chloride using pyridine in CH₂Cl₂. Deprotection of [2-(acetylamino)thiazol-4-yl]methyl acetate using K₂CO₃ in MeOH, followed by reaction of the resulting alc. with MnO₂ in MeOH/CHCl₃ provided N-(4-formylthiazol-2-yl)acetamide. Coupling of the aldehyde with 1-(bromomethyl)-4-nitrobenzene in the presence of PPh₃ and t-BuOH in DMF gave N-[4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide, which was reduced to the amine with Pd/C in MeOH/THF/AcOH. Finally, coupling of the amine with cyanamide in the presence of HCl in EtOH/EtOAc afforded II. The latter inhibited VAP-1 enzyme (SSAO) activity in both human and rat plasma (IC₅₀ = 0.15 μM and 0.012 μM, resp.), but not the enzyme activities of other amine oxidases (IC₅₀ >100 μM), such as human platelet monoamine oxidase (MAO) and cloned diamine oxidase (DAO, histaminase). Treatment of diabetic rats daily with II (10 mg/kg/ s.c. u.i.d.) improved their ocular permeability in comparison with the diabetic control group (vitreous/plasma ratio of fluorescein concns. = 5.39 ± 0.73 x10⁻³ and 8.93 ± 1.14 x10⁻³, resp.). Thus, I and their pharmaceutical compns. are useful for preventing or treating VAP-1 associated diseases, especially macular edema (no data).


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:506123 CAPLUS


DOCUMENT NUMBER: 127:205746

TITLE: Synthesis of methyl 2-acetylamino-5-(1,3-dithian-2-


yl)thiazole-4-carboxylate
 AUTHOR(S): Feliu, Lidia; Ajana, Wadi; Joule, John A.;
 Lopez-Calahorra, Francisco; Alavarez, Mercedes
 CORPORATE SOURCE: Laboratori de Quimica Organica, Facultat de Farmacia,
 Univ. de Barcelona, Barcelona, 08028, Spain
 SOURCE: Heterocycles (1997), 45(7), 1299-1308
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 127:205746
 IT **194663-84-8P 194663-88-2P 194663-89-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis of Me 2-acetylamino-5-(1,3-dithian-2-yl)thiazole-4-
 carboxylate)
 RN 194663-84-8 CAPLUS
 CN 4-Thiazolecarboxamide, 2-(acetylamino)-N-phenyl- (9CI) (CA INDEX NAME)



RN 194663-88-2 CAPLUS
 CN 4-Thiazolecarboxamide, 2-(acetylamino)-5-formyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 194663-89-3 CAPLUS
 CN 4-Thiazolecarboxamide, 2-(acetylamino)-5-(1,3-dithian-2-yl)-N-phenyl-
 (9CI) (CA INDEX NAME)



AB The synthesis of Me 2-acetylamino-5-(1,3-dithian-2-yl)thiazole-4-
 carboxylate by formylation of a 4-substituted thiazole and then reaction
 with 1,3-propanedithiol is described as a model for synthesis of

10/764,529

thiazolopyridoacridine alkaloids. The utility of different ortho-directing groups (ODGs) for the lithiation of the thiazole 4-position has been studied.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
20.90	188.05

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.00	-3.00

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:28:55 ON 07 FEB 2006